

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<u>http://bmjopen.bmj.com</u>).

If you have any questions on BMJ Open's open peer review process please email <u>info.bmjopen@bmj.com</u>

BMJ Open

Impact of rescue triggered inhaled corticosteroids on controller therapy in Black and Latinx Individuals

| Journal: | BMJ Open |
|----------------------------------|---|
| Manuscript ID | bmjopen-2024-088349 |
| Article Type: | Original research |
| Date Submitted by the Author: | 03-May-2024 |
| Complete List of Authors: | Callen, Elisabeth; DARTNet Institute, Israel, Elliot; Brigham and Women's Hospital Cardet, Juan Carlos; University of South Florida Fuhlbrigge, Anne L ; University of Colorado Manning, Brian; DARTNet Institute Gaona, Gabriela; DARTNet Institute Staton, Elizabeth; University of Colorado Denver Anschutz Medical Campus Pace, Wilson; DARTNet Institute, Research |
| Keywords: | Patients, Asthma < THORACIC MEDICINE, STATISTICS & RESEARCH METHODS |
| | |





I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our <u>licence</u>.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which <u>Creative Commons</u> licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

terez oni

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies



| 1 2 | | |
|----------------------------------|----|---|
| 2 3 4 | 1 | Impact of rescue triggered inhaled corticosteroids on controller therapy in Black and |
| 5 6 7 | 2 | Latinx Individuals |
| 7 8 9 | 3 | |
| 10 11 | 4 | Elisabeth F. Callen, PhD ^{1,2*} , Elliot Israel, MD ³ , Juan Carlos Cardet, MD, MPH ⁴ , Anne |
| 12 13 | 5 | L. Fuhlbrigge, MD, MS ⁵ , Brian K. Manning, MPH ^{1,2} , Gabriela Gaona, MPH, CPH ² , |
| 14 15 16 | 6 | Elizabeth W. Staton, MSTC ^{2,6} , Wilson D. Pace, MD, FAAFP ² |
| 17 18 | 7 | ¹ American Academy of Family Physicians National Research Network, Leawood, |
| 19 20 21 | 8 | Kansas, United States of America |
| 21 22 23 | 9 | ² DARTNet Institute, Aurora, Colorado, United States of America |
| 24 25 | 10 | ³ Division of Pulmonary and Critical Care Medicine and Division of Allergy and |
| 26 27 | 11 | Immunology, Brigham and Women's Hospital, Boston, Massachusetts, United States of |
| 28 29 30 | 12 | America |
| 31 32 | 13 | ⁴ Division of Allergy and Immunology, Department of Internal Medicine, University of |
| 33 34 | 14 | South Florida, Morsani College of Medicine, Tampa, Florida, United States of America |
| 35 36 37 | 15 | ⁵ Pulmonary Science and Critical Care Medicine, Department of Medicine, University of |
| 38 39 | 16 | Colorado School of Medicine, Aurora, Colorado, United States of America |
| 40 41 | 17 | ⁶ University of Colorado Department of Family Medicine, Aurora, Colorado, United |
| 42 43 44 | 18 | States of America |
| 44 45 46 | 19 | |
| 47 | 20 | *Corresponding Author: |
| 48 49 50 | 21 | Email: elisabeth.callen@dartnet.info |
| 51 | 22 | |
| 52 53 54 55 56 57 | 23 | |
| 58 59 | | 1 |
| 60 | | For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml |

Page 3 of 31

BMJ Open

| 24 | Abstract |
|----|---|
| 25 | Objective: The Person Empowered Asthma Relief (PREPARE) study found that as- |
| 26 | needed inhaled corticosteroid supplementation combined with participants' usual |
| 27 | controller and rescue therapy reduced asthma exacerbations. Here we sought to |
| 28 | determine if treatment assignment to the Intervention (called PARTICS) vs Control |
| 29 | (Usual Care) had an impact on controller therapy based on clinicians' written |
| 30 | prescriptions. Design: Secondary data analysis. Setting: Practices treating asthma. |
| 31 | Participants: PREPARE study participants were included in this analysis. |
| 32 | Interventions: PREPARE study. Outcome Measures: For impact of the PARTICS |
| 33 | therapy on patients, each patient-month was assigned to a controller step based on a 6- |
| 34 | step classification scheme. An overall Linear Mixed Effect Model was completed for all |
| 35 | 28 months of data and a Linear Mixed Effect Spline Model was completed for before |
| 36 | and after enrollment data to determine controller changes over a 28-month period (12 |
| 37 | months prior to enrollment, the month of enrollment, and 15 months after enrollment) |
| 38 | between the two study arms. Results: This analysis included 713 participants. Of these, |
| 39 | 49.1% were Usual Care patients and 50.9% were PARTICS patients. Throughout the |
| 40 | study, the majority of patients changed asthma controller medications in both arms. By |
| 41 | the end of the study, the Usual Care patients were at a significantly higher asthma |
| 42 | controller medication step (0.20 step higher) than the PARTICS patients. Conclusions: |
| 43 | Clinicians' prescribing patterns showed significant changes over time. Compared with |
| 44 | Usual Care patients, PARTICS patients were on lower doses of asthma controller |
| 45 | medications by the end of the study. |
| 46 | |

Strengths and Limitations of This Study: This paper presents the results of an electronic health record analysis of controller medications prescribed from 12 months before enrollment into the Person Empowered Asthma Relief (PREPARE) study through 15 months after enrollment. The results show, from a provider perspective, that the patients enrolled in PREPARE and assigned to the intervention arm were using less asthma controller medications by the end of the study than patients assigned to the control arm. Limitations: EHR data have inherent missingness and can have gaps due to infrequent visits and prescribing activities. Some individuals were on dual ICS inhalers not counting the study-prescribed beclomethasone, and these individuals were assigned based on the highest potency of any of the non-study prescribed ICS inhalers. In addition, not every site within PREPARE provided data, but we had data from the majority of sites.

Page 5 of 31

| | 62 | INTRODUCTION |
|-------------|----|---|
| | 63 | Twenty-five million adults have asthma in the US.(1) Asthma exacerbations cause the |
| | 64 | largest number of lost days from school or work for children and young adults, one-third |
|) | 65 | of all days.(2, 3) Despite new medications,(4, 5) new drug regimens,(6-11) and the |
| | 66 | ongoing evolution of treatment guidelines(12-14) the number of people with asthma |
| - | 67 | exacerbations in the previous year has decreased only slightly over the past 20 years, |
| , | 68 | from 51.6% to 46.0%.(15, 16) Asthma is also a disease with a high degree of disparities |
|) | 69 | in outcomes. Blacks have exacerbation and death rates that are 2-2.5 times higher than |
| | 70 | Whites and Asians,(17) while Hispanics, particularly Caribbean Hispanics,(18, 19) have |
| - | 71 | 2 times the rate of exacerbations and 1.5 times the death rate.(20, 21) Thus, there is an |
|) | 72 | ongoing need to expand and improve treatment approaches for individuals with asthma. |
|) | 73 | |
|) | 74 | The paradigm concerning use of inhaled corticosteroids (ICS) only as a controller, i.e., |
| | 75 | as a once or twice a day medication, has been evolving. The use of ICS-formoterol as |
| | 76 | both controller and rescue therapy (single maintenance and reliever therapy [SMART]) |
| | 77 | is endorsed by multiple guideline groups across the world, include the US, GINA, and |
|) | 78 | UK guidelines.(12, 14, 22) Previous randomized controlled trials have also |
| | 79 | demonstrated that as-needed, stand-alone, ICS use in conjunction with short acting |
| | 80 | beta-agonist (SABA) for acute asthma symptom relief can improve asthma outcomes.(7, |
|) , | 81 | 23-29) The Person Empowered Asthma Relief (PREPARE) trial utilized a stand-alone |
| ,)) | 82 | ICS combined with participants' usual controller and rescue therapy in an approach |
| | 83 | called Patient Activated Reliever-Triggered ICS (PARTICS).(30) |
| - | 84 | |
|) | | |

BMJ Open: first published as 10.1136/bmjopen-2024-088349 on 21 November 2024. Downloaded from http://bmjopen.bmj.com/ on June 13, 2025 at Agence Bibliographique de l Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

Enseignement Superieur (ABES). Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies

The PARTICS intervention decreased asthma exacerbations, improved asthma control and guality of life, and reduced reliever use in African American/Black (AA/B) and Hispanic/Latinx (H/L) adults with moderate to severe asthma, a group with disproportionate asthma morbidity that has been difficult to reduce.(30) This research extended the general concept of using ICS with all rescue beta-agonist use, whether long- or short-acting. It also demonstrated effectiveness, through changes in validated assessments, in AA/B and H/L adults, integrated with rescue nebulizer therapy, required no changes in a participant's current controller therapy, and appears to have fewer insurance barriers than an ICS-formoterol based approach. Participants on PARTICS also reported lower SABA use, both as a metered dose inhaler and via nebulizer, and fewer controller refills as well as a self-reported reduction in controller ICS dosage.(30) The objective of this paper is to report on a pre-specified PREPARE trial sub-analysis using electronic health record (EHR) data to determine if treatment assignment (the PARTICS intervention vs. usual care) had an impact on controller therapy through clinicians' written prescriptions. The analysis compares changes in controller intensity (e.g., low, medium, or high ICS dose) as determined by EHR data over a 28-month period (12 months prior to enrollment, month of enrollment, and 15 months after enrollment) between the two arms of the study. METHODS **Brief Description of the PREPARE Study**

| 1 2 | | | | | | | |
|--|-----|--|---|--|--|--|--|
| 3 4 | 108 | | | | | | |
| 5 6 7 | 109 | The PREPARE study was a pragmatic, open label, patient level randomized trial | | | | | |
| 8 | 110 | designed to observe the effects of adding ICS to rescue therapy among AA/B and H/L | | | | | |
| 2 3 4 5 6 7 | 111 | adults with moderate-to-severe asthma.(31) In the PREPARE study, the | | | | | |
| 13 | 112 | Intervention/PARTICS group (hereafter, "PARTICS group") received additional ICS | | | | | |
| 15 | 113 | medication (donated by TEVA, beclomethasone 80 mcg) and was asked to use 1 puff o | f | | | | |
| 17 | 114 | beclomethasone for every 1 puff of usual rescue inhaler and 5 puffs of beclomethasone | | | | | |
| 19 | 115 | for every 1 rescue nebulization, in addition to usual care. The control group received | | | | | |
| 22 | 116 | usual care (hereafter, "UCare group"), described previously.(31) Exacerbations were | | | | | |
| 24 | 117 | tracked using patient-reported outcomes that were adjudicated using EHR data and | | | | | |
| 26 | 118 | patient interviews. The sub-study detailed here covers the prescriber side of asthma | | | | | |
| 28 29 30 31 32 33 34 35 36 | 119 | controller medications, as recorded in the EHRs of the primary asthma treating clinician | | | | | |
| | 120 | (primary care, pulmonologist or allergist) for a subset of enrollees. To determine the | | | | | |
| | 121 | effect, we analyzed PREPARE participants' asthma controller medications over 28 | | | | | |
| | 122 | months (12 months before enrollment into PREPARE, month of enrollment into | | | | | |
| 38 | 123 | PREPARE, and 15 months after enrollment). | | | | | |
| 40 | 124 | FHP Data Acquisition | | | | | |
| | 125 | EHR Data Acquisition | | | | | |
| 44 45 46 47 48 | 126 | | | | | | |
| | 127 | Each site was asked to provide EHR data for each participant within the PREPARE | | | | | |
| 49 50 | 128 | study. The DARTNet Institute provided a set of instructions for each site including the | | | | | |
| 51 52 | 129 | variables needed from the EHR. Sixteen of the 19 participating sites provided data from | | | | | |
| 53 54 55 | 130 | their EHR or data warehouse. Requested information included care site information, | | | | | |
| 55 56 57 | | | | | | | |
| 58 59 | | | 6 | | | | |
| 60 | | For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml | - | | | | |

Page 8 of 31 BMJ Open: first published as 10.1136/bmjopen-2024-088349 on 21 November 2024. Downloaded from http://bmjopen.bmj.com/ on June 13, 2025 at Agence Bibliographique de Enseignement Superieur (ABES)

Protected by copyright, including for uses related to text

and

data mining, Al training, and similar technologies

BMJ Open

patient visits, medications, diagnostic codes, and procedures. Each participating site provided a pilot data pull that was standardized to the Observational Medical Outcomes Partnership Common Data Model v5.4 (OMOP CDM v5.4) and reviewed for data quality. Data quality concerns were communicated back to the sites; in some cases, new data were submitted. After all patients from a given site had exited the study, that site re-pulled their data and sent it to DARTNet for data standardization. (Note: One site, Site 6, did not provide data for their patients from before their enrollment into PREPARE.) **EHR Data Standardization** DARTNet utilized its standard procedures (python scripts and SQL coding) to transform the data received from each site into the OMOP CDM v5.4.(32) Briefly, data were loaded into a receiving database. As data were moved into the final OMOP data model, known taxonomies were auto-mapped to source OMOP concept IDs and a "standard" OMOP concept ID. Source data using idiosyncratic codes were hand-mapped and processed through to the OMOP data model. Data guality reports were evaluated for all relevant sets of conditions, medications, procedures, and measures. Final data were sent to the American Academy of Family Physicians (AAFP) for cleaning and analysis. EHR Data Cleaning

60

| 1 2 | | |
|----------------|-----|--|
| - 3 4 | 153 | Once the standardized data were received from DARTNet, the individual site files were |
| 5 6 | 154 | combined for analysis. DARTNet worked with the AAFP to review and modify, if |
| 7 8 9 | 155 | needed, existing "value sets" (i.e., list of codes associated with clinical concepts- either |
| 10 11 | 156 | specific medications, conditions, or procedures). Value sets were created that |
| 12 13 | 157 | segregated asthma medications as specifically needed for this analysis. Medications |
| 14 15 | 158 | were categorized on a monthly basis as active using the following rules: |
| 16 17 18 | 159 | Start date of medication: The month the prescription was written was considered |
| 19 20 | 160 | the start date/month. |
| 21 22 | 161 | End date of medication: |
| 23 24 25 | 162 | \circ If an end date was provided, then it was used if it was 12 months or less |
| 26 27 | 163 | from the time the prescription was written. |
| 28 29 | 164 | \circ If no end date was provided, then an end date of 12 months after the |
| 30 31 32 | 165 | prescription was written was used. |
| 32 33 34 | 166 | Dosage/quantity and refills provided were also used to determine if a 12-month |
| 35 36 | 167 | end date was appropriate or a shorter time span should be used due to how the |
| 37 38 | 168 | prescription was written. |
| 39 40 41 | 169 | Once each asthma medication for each patient had assigned months, all medications |
| 42 43 | 170 | were assigned to types of asthma medications (e.g., low/medium/high dose ICS, Long- |
| 44 45 | 171 | Acting Beta-Agonists (LABA), Long-Acting Muscarinic Antagonist (LAMA)). Using those |
| 46 47 48 | 172 | assigned types, all medications for each patient were collapsed into one record for each |
| 49 50 | 173 | month (patient-month). The medication types for each month were assigned to a |
| 51 52 | 174 | controller step based on highest ICS dose (i.e., low, medium, high) that they were |
| 53 54 55 | 175 | prescribed along with additional controller medications. |
| 56 57 | | |
| 58 59 | | 8 |
| 60 | | For peer review only - http://bmiopen.bmi.com/site/about/guidelines.xhtml |

| BMJ C | Dpen |
|-------|------|
|-------|------|

| 1 2 | | |
|----------------------------------|-----|--|
| 2 3 4 | 176 | |
| 5 6 | 177 | Outcome Groupings |
| 7 8 9 | 178 | |
| 10 11 | 179 | Each patient-month was assigned to a controller step based on a six-step classification |
| 12 13 | 180 | scheme. The hierarchy of controller step levels (located in Supplemental Materials) was |
| 14 15 16 | 181 | based on Guideline Steps (hereafter referred to as step) outlined in the National Asthma |
| 17 18 | 182 | Education and Prevention Program (NAEPP) guidelines.(14) If a patient had no |
| 19 20 | 183 | medication used within the classification scheme, then the patient was assigned a "0" |
| 21 22 | 184 | for the month indicating the patient had no asthma controller medications prescribed to |
| 23 24 25 26 27 | 185 | him/her within a given month. The six-step classification scheme (plus "0" for no |
| | 186 | medication) was used as the dependent variable in the statistical models. |
| 28 29 | 187 | |
| 30 31 32 | 188 | Statistical Methods |
| 33 34 | 189 | |
| 35 36 | 190 | This analysis was a secondary data analysis. Descriptive and inferential statistics were |
| 37 38 39 | 191 | completed as appropriate. To start, changes in asthma controller medication were |
| 40 41 | 192 | determined by the starting and stopping of prescriptions according to the EHR data |
| 42 43 | 193 | rules. A change was the movement up or down in the step hierarchy. Then to model the |
| 44 45 | 194 | EHR data, Linear Mixed Effect Model (LME; overall model and a spline version) were |
| 46 47 48 | 195 | used with the assigned asthma controller medication step in each month as the |
| 49 50 | 196 | dependent variable; independent variable(s) varied depending on the model. A series of |
| 51 52 | 197 | LMEs were completed to determine the individual demographic variables that |
| 53 54 55 56 57 58 | 198 | contributed (p < 0.05) to the model. The dependent variable for all LMEs was the six- |

Page 11 of 31

BMJ Open

step classification scheme described above. If a demographic variable was considered to have contributed, then the variable was included in the final models discussed below. We also included a COVID-19 correction variable to account for any possible changes in asthma controller medications that occurred due to the COVID-19 pandemic (i.e., 0=No COVID-19 pandemic present; 1=COVID-19 pandemic present). Due to the nature of the data and the autocorrelation present, the covariance matrix used was a Heterogeneous First-Order Autoregressive to account for the previous month's influence. LMEs were used due to the ability to cluster to the person/patient, the acceptance of potentially missing data, and that it also works for data that violate any distributional assumptions. (33-35) An overall LME was completed for all 28 months of data (located in the Supplemental Materials) and a LME with Spline was completed for before and after enrollment data. For the final LMEs, the random variables were intercept, clustered to the patient. The fixed variables were patient-month, group (PARTICS/UCare), site, decade of birth, and COVID-19 correction. An alpha of 0.05 was used. All analyses were completed using SAS 9.4 (Cary, NC). RESULTS **Demographics** After cleaning EHR data obtained from each site, there were 713 participants (out of 1,201 participants randomized in PREPARE) included in these analyses. The remaining patients in the PREPARE study (488) did not have their data included because the sites

Protected by copyright, including for uses related to text

data mining, Al training, and similar technologies

did not provide EHR data. The breakdown of participants by site is in Table 1. Of these, 350 (49.1%) were in the UCare Group and 363 (50.9%) were in the PARTICS Group. Most participants were female and Non-Hispanic/Black (Table 2 for comparisons with the full study cohort). As the University of Puerto Rico, a major H/L enrolling site, was not able to provide EHR data, the cohort of participants included in this analysis has a lower percent of H/L participants than the full study (p<0.001; Table 2).

Table 1. Counts of Participants used in the EHR Data by Site (n = 713).

| Site | Count 🦯 | P |
|---------|---------|---|
| Site 1 | 14 | |
| Site 2 | 21 | |
| Site 3 | 58 | |
| Site 4 | 34 | |
| Site 5 | 57 | |
| Site 6 | 79 | |
| Site 7 | 86 | |
| Site 8 | 16 | |
| Site 9 | 48 | |
| Site 10 | 58 | |
| Site 11 | 42 | |
| Site 12 | 9 | |
| Site 13 | 71 | |
| Site 14 | 70 | |

| Site 15 | 13 |] | | |
|---------------------|---------------|-------------------|------------------------|-------------------------|
| | | _ | | |
| Site 16 | 37 | | | |
| | | | | |
| Table 2. Demogra | aphics and | l Comparisons | with Main Study (n | (%)). |
| | PART | ICS (n = 363) | UCare (n = 350) | Sig with Main Stuc |
| Overall (n = 713) | 36 | 63 (50.9%) | 350 (49.1%) | 0.722 |
| Female | 29 | 97 (81.8%) | 292 (83.4%) | 0.295 |
| Non-Hispanic/Bla | ack 21 | 6 (59.5%) | 217 (62.0%) | <0.001 |
| | | | | 1 |
| Changes in Asth | ma Contro | ller Medicatior | Prescriptions | |
| | | | | |
| As noted in Table | 3, asthma | controller medic | ation prescription ch | anges, without regar |
| to the change dire | ection, occu | rred over time (| before and after enro | Ilment; comparison |
| two time points) fo | or both the l | JCare and PAR | TICS groups. Chang | es included addition |
| withdrawal of inha | lers or med | lications, biolog | ics, and leukotriene i | nhibitors, as well as |
| | e of all med | lications. Howev | ver, changes were st | atistically similar, so |
| changes in dosag | | | | |
| 0 0 | ged controll | er medications | with similar frequenc | y over the various tir |
| 0 0 | - | er medications | with similar frequenc | y over the various ti |
| poth groups chang | - | er medications | with similar frequenc | y over the various tir |

Overall (n = 713)

PARTICS (n =

363)

UCare (n = 350)

6

| 12 Months Prior to Enrollment – Enrollment Month | | |
|---|--|--|
| Changes Occurred 451 (63.3%) 219 (60.3%) 232 (66.3%) | | |
| Enrollment Month – 15 Months After Enrollment | | |
| Changes Occurred 491 (68.9%) 247 (68.0%) 244 (69.7%) | | |
| Enrollment Month – 12 Months After Enrollment | | |
| Changes Occurred 477 (66.9%) 239 (65.8%) 238 (68.0%) | | |
| | | |
| Modelling of Electronic Health Record Data | | |
| | | |
| After models with the individual demographic variables were completed (not shown), | | |
| each model contained the assigned step each month as the dependent variable and t | | |
| month, the group (PARTICS or UCare), the site, the patients' decade of birth, and | | |
| COVID-19 correction as independent variables. After the final overall model (located i | | |
| the Supplemental Materials), a spline was introduced to determine the differences | | |
| between before and after Enrollment and to determine the effect of the intervention | | |
| using prescribers' written prescriptions. The next two models detail the LME with Splin | | |
| accounting for before Enrollment (Table 4) and after Enrollment (Table 5). | | |
| | | |
| Model for Before Enrollment (12 months prior through one month before | | |
| Enrollment; Table 4) | | |
| | | |
| Table 4. Final Before Enrollment LME Results. | | |
| | | |
| | | |
| | | |
| For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml | | |

Page 15 of 31

| Parameter | Estimate | Standard | 95% CI | t |
|----------------------|-------------------|-----------------------|---------------|-------|
| | | Error | | |
| | -2 Restricted Lo | og Likelihood: 24 | 603.78 | |
| | Month: F(1, 568 | - | | |
| | | | | |
| | | 19.00) = 0.01; p | | |
| | Site: F(14, 549 | 9.00) = 8.47; p < | 0.001 | |
| De | ecade of Birth: F | (4, 549.00) = 2.6 | 0; p = 0.04 | |
| Intercept (Baseline) | 2.80 | 0.30 | [2.20, 3.39] | 9.20 |
| Month | 0.15 | 0.01 | [0.13, 0.17] | 14.10 |
| UCare | 0.01 | 0.11 | [-0.20, 0.22] | 0.08 |
| PARTICS | | Refe | rence | |
| | 0.10 | <u> </u> | | 0.04 |
| Site 1 | -0.10 | 0.46 | [-1.00, 0.81] | -0.21 |
| Site 2 | 1.12 | 0.38 | [0.38, 1.86] | 2.98 |
| Site 3 | 1.21 | 0.28 | [0.65, 1.76] | 4.29 |
| Site 4 | 0.62 | 0.32 | [-0.01, 1.25] | 1.93- |
| Site 5 | 1.50 | 0.28 | [0.95, 2.06] | 5.33 |
| Site 6 | N/A | N/A | N/A | N/A |
| Site 7 | 0.72 | 0.27 | [0.20, 1.24] | 2.72 |
| Site 8 | 0.11 | 0.41 | [-0.70, 0.92] | 0.28 |
| Site 9 | 0.43 | 0.29 | [-0.15, 1.01] | 1.46 |
| Site 10 | -0.18 | 0.29 | [-0.75, 0.40] | -0.61 |
| Site 11 | 0.10 | 0.31 | [-0.51, 0.72] | 0.33 |
| Site 12 | -0.84 | 0.48 | [-1.80, 0.11] | -1.74 |

Protected by copyright, including for uses related to text

and

data mining, AI training, and similar technologies

| p-value < 0.05 | 9 | | | |
|---------------------|-------|------|----------------|--------|
| Born: 1990s & 2000s | No. | Re | ference | |
| Born: 1980s | 0.20 | 0.23 | [-0.26, 0.65] | 0.84 |
| Born: 1970s | 0.10 | 0.22 | [-0.34, 0.54] | 0.43 |
| Born: 1960s | 0.16 | 0.22 | [-0.27, 0.58] | 0.73 |
| Born: 1940s & 1950s | 0.52 | 0.22 | [0.09, 0.94] | 2.38* |
| Site 16 | | Ret | ference | |
| Site 15 | -1.46 | 0.46 | [-2.36, -0.55] | -3.16* |
| Site 14 | 0.25 | 0.28 | [-0.30, 0.79] | 0.89 |
| Site 13 | 0.26 | 0.27 | [-0.28, 0.79] | 0.95 |

The UCare and PARTICS patients were at approximately the same step before enrollment. The months before Enrollment did show a significant decrease in controller intensity over time (months were inputted as negative value). (Note: The data for before Enrollment took place entirely before the start of the COVID-19 pandemic.) The assigned steps differed significantly between the sites. Four sites (Sites 2, 3, 5, 7) had significantly higher steps of asthma controller medications compared with patients from Site 16 (reference site). One site (Site 15) had significantly lower steps of asthma controller medications than patients from Site 16. The assigned steps differed significantly with the patients' decade of birth. Patients born in the 1940s/1950s had significantly higher levels of asthma controller medications than

- patients born in the 1990s/2000s (Table 4).

 60

| 75 | | | | | |
|----|-------------------------|--------------------|-------------------|-------------------|-----------|
| 76 | Model After Enrollmen | it (one month al | fter through the | e 15 months after | r Enrollm |
| 77 | Table 5) | | | | |
| 78 | | | | | |
| 79 | Table 5. Final After En | rollment LME R | esults. | | |
| | | | | | |
| | Parameter | Estimate | Standard Error | 95% CI | t |
| | | -2 Restricted Lo | bg Likelihood: 33 | 3387.07 | |
| | | Month: F(1, 684 | 1.72) = 24.59; p | < 0.001 | |
| | | Group: F(1, 63 | 31.01) = 4.72; p | = 0.03 | |
| | | Site: F(15, 633 | 3.60) = 9.91; p < | 0.001 | |
| | Dee | cade of Birth: F(4 | 4, 631.09) = 3.83 | 3; p = 0.004 | |
| | COVI | D Correction: F(| 1, 9448.26) = 29 | .68; p < 0.001 | |
| | Intercept (Baseline) | 2.04 | 0.29 | [1.48, 2.60] | 7.16* |
| | Month | -0.05 | 0.01 | [-0.06, -0.03] | -4.95 |
| | UCare | 0.20 | 0.09 | [0.02, 0.39] | 2.17* |
| | PARTICS | | Refe | rence | |
| | Site 1 | -0.37 | 0.39 | [-1.13, 0.40] | -0.94 |
| | Site 2 | 1.40 | 0.33 | [0.75, 2.05] | 4.20* |
| | Site 3 | 1.57 | 0.26 | [1.05, 2.09] | 5.97* |
| | Site 4 | 1.31 | 0.29 | [0.74, 1.89] | 4.49* |
| | Site 5 | 0.96 | 0.26 | [0.44, 1.48] | 3.63* |
| | Site 6 | -0.03 | 0.25 | [-0.52, 0.45] | -0.14 |

| Born: 1980s | 0.30 | 0.20 | [-0.09, 0.69] | 1.49 |
|---------------------|-------|------|----------------|--------|
| Born: 1970s | 0.24 | 0.19 | [-0.13, 0.62] | 1.27 |
| Born: 1960s | 0.00 | 0.18 | [-0.36, 0.36] | 0.01 |
| Born: 1940s & 1950s | 0.46 | 0.19 | [0.10, 0.83] | 2.49* |
| Site 16 | 0 | Ref | erence | |
| Site 15 | -1.36 | 0.45 | [-2.24, -0.48] | -3.03* |
| Site 14 | 0.56 | 0.26 | [0.05, 1.08] | 2.17* |
| Site 13 | -0.17 | 0.27 | [-0.69, 0.35] | -0.64 |
| Site 12 | 0.31 | 0.47 | [-0.62, 1.23] | 0.65 |
| Site 11 | 0.59 | 0.29 | [0.02, 1.15] | 2.05* |
| Site 10 | 0.43 | 0.26 | [-0.08, 0.94] | 1.65+ |
| Site 9 | 0.41 | 0.28 | [-0.13, 0.95] | 1.49 |
| Site 8 | 0.43 | 0.39 | [-0.34, 1.20] | 1.09 |
| Site 7 | 0.57 | 0.25 | [0.08, 1.06] | 2.30* |

> The UCare patients were at a significantly higher asthma controller medication step overall than the PARTICS patients across all time periods for the time after Enrollment. However, the months after Enrollment did show a significant decrease in controller intensity over time for both groups, which could be due to the COVID-19 pandemic.

> > For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Page 19 of 31

BMJ Open

| 1 2 | | |
|----------------|-----|------|
| 3 4 | 286 | Wh |
| 5 6 | 287 | PA |
| 7 8 | 288 | sigr |
| 9 10 11 | 289 | UC |
| 12 13 | 290 | |
| 14 15 | 291 | The |
| 16 17 18 | 292 | 7, 1 |
| 19 20 | 293 | fror |
| 21 22 | 294 | con |
| 23 24 25 | 295 | sigr |
| 25 26 27 | 296 | sigr |
| 28 29 | 297 | 199 |
| 30 31 | 298 | 202 |
| 32 33 34 | 299 | leve |
| 35 36 | 300 | |
| 37 38 | 301 | DIS |
| 39 40 41 | 302 | Thi |
| 42 43 | 303 | dec |
| 44 45 | 304 | PA |
| 46 47 48 | 305 | red |
| 40 49 50 | 306 | fror |
| 51 52 | 307 | con |
| 53 54 | 308 | con |
| 55 56 57 | | |
| 58 | | |
| 59 | | |

60

en compared to the Model Before Enrollment, the difference between the UCare and RTICS patients with the changes over time indicate that the PARTICS patients had nificantly greater decrease in the intensity of their controller therapy compared to are patients (Tables 4 and 5).

e assigned steps differed significantly between the sites. Seven sites (Sites 2, 3, 4, 5, 1, 14) had significantly higher steps of asthma controller medications than patients m Site 16 (reference site). One site (Site 15) had significantly lower steps of asthma troller medications than patients from Site 16. The assigned steps differed nificantly with the patients' decade of birth. Patients born in the 1940s/1950s had nificantly higher levels of asthma controller medications than patients born in the 90s/2000s. Lastly, in the months when COVID-19 was not present (before April 20), both groups of patients had a significantly higher asthma controller medication el than after the COVID-19 pandemic began (Table 5).

SCUSSION

s study shows, through prescribers' written prescriptions, there was a greater crease in asthma controller medication level over time (after Enrollment) in the RTICS patients compared with the UCare patients. The decrease in intensity uces, to some degree, the expected increase in total ICS exposure that would result m adopting the PARTICS strategy. The results in this sub-study complement and ifirm the results in the main effects paper that that shows that self-reported ICSntaining controller refills were lower for participants assigned to PARTICS vs usual

Protected by copyright, including for uses related to text

and

ur (ABES) . data mining, Al training, and similar technologies

care.(30) Between this sub-study and the main effects paper, the participants' reported and prescribers' EHR data indicate decreased asthma controller medication use over time for the PARTICS patients compared with the UCare patients, even with correcting for COVID-19. When combined with the patient self-reported levels of controller ICS use and rescue ICS fulfillment data from the main effects paper, this sub-study supports that PARTICS improves outcomes at the population level, as the intensity of ICS controller therapy dropped as well as self-reported controller ICS use. Treating clinicians were free to adjust asthma medications as deemed necessary during the study. Primary asthma treating clinicians were not provided the monthly Asthma Control Test scores that were collected for research purposes, but patients may have been more aware of their asthma symptoms through repeated completion of this instrument. For many patients the primary asthma treating clinician was not the research prescribing clinician, but the treating clinician would have been aware of the study medication. While it is not possible to determine if the drop in controller ICS dose, at the population level, was in response to the added as needed ICS, the increase in controller ICS dosage for the control patients would suggest changes were more likely to be based on asthma control and not perceived total steroid burden.

While the results of this sub-study confirm the results of the main effects paper, there are limitations. EHR data have inherent missingness and can have gaps due to infrequent visits and prescribing activities. In particular, assumptions concerning the length of time a prescription was active were made to determine an active medical regimen. While this may have affected the exact level for a given individual, the

Page 21 of 31

BMJ Open

assumptions were evenly applied across both groups. Further, some individuals were on dual ICS inhalers not counting the study-prescribed beclomethasone, and these individuals were assigned based on the highest potency of any of the non-study prescribed ICS inhalers. Again, while this may have affected the ICS level of an individual, the approach was evenly applied at all times across both groups. Thus, neither of these processes would bias the results for either of the study arms. In addition, not every site within PREPARE provided data, but we had data from the majority of sites. This reduction in ICS controller intensity in the PARTICS group was accompanied with a significant reduction in annualized exacerbation rates in this group, (30) though total ICS use considering both controller and rescue use likely increased to some degree.

The results show that there were significant changes over time (after Enrollment) as well as significant differences between the PARTICS and UCare groups, participating sites, participants' decades of birth, and the COVID-19 correction. In the spline regressions, the UCare and PARTICS patients were comparable before enrollment, and differences occurred after enrollment in PREPARE. This effect is consonant with our reported reduction in exacerbations in the PREPARE cohort during the COVID pandemic. (36) The significant effect due to COVID-19 could be due to a variety of factors including changes in lifestyles that occurred such as working from home and a reduction in air pollution due to fewer cars on the road. (36) This effect could be further studied using air pollution data around the patents' dwellings.

and

Protected by copyright, including for uses related to text

| 355 | Select sites provided their patients with significantly higher (or lower) asthma controller |
|-----|---|
| 356 | medications than the reference site (Site 16). The differences could be accounted for by |
| 357 | different overall participant asthma severity across sites,(31) clinicians' prescribing |
| 358 | patterns, organizational policies, or environmental factors. Though all clinicians |
| 359 | providing asthma care for PREPARE participants completed the Asthma IQ |
| 360 | program(37) to help standardize care, this intervention would not affect baseline (or pre- |
| 361 | baseline) prescribing patterns, which were in place prior to the training. Further |
| 362 | exploration into the reasons for the differences is warranted. |
| 363 | |
| 364 | This sub-study shows that clinicians' prescribing patterns did change over time, and the |
| 365 | PARTICS patients were prescribed lower doses of asthma controller medications by the |
| 366 | end of the study. |
| 367 | |
| 368 | Acknowledgements: We would like to acknowledge all study participants for their time |
| 369 | and dedication. We would also like to acknowledge the PREPARE Operations Team |
| 370 | and Nancy Maher. We would also like to acknowledge the PREPARE site principal |
| 371 | investigators. |
| 372 | |
| 373 | Availability of Data: Data available upon reasonable request to the corresponding |
| 374 | author. |
| 375 | |
| 376 | Patient and Public Involvement: Patients and the public were not involved in the |
| 377 | design, conduct, reporting, and dissemination of this secondary data analysis. |
| | |

| 1 2 | | |
|----------------|-----|--|
| 3 4 | 378 | |
| 5 6 | 379 | Financial Support: Supported by a PCORI Award (PCS-1504-30283, to Dr. Israel), the |
| 7 8 9 | 380 | Gloria M. and Anthony C. Simboli Distinguished Chair in Asthma Research award (to |
| 9 10 11 | 381 | Dr. Israel), and by grants from the National Institute of Allergy and Infectious Diseases |
| 12 13 | 382 | (K23AI125785, to Dr. Cardet) and the American Lung Association–American Academy |
| 14 15 | 383 | of Allergy, Asthma, and Immunology (AI-835475, to Dr. Cardet). QVAR and QVAR |
| 16 17 18 | 384 | RediHaler inhalers were provided free of charge and funding for the AssistRx pharmacy |
| 19 20 | 385 | was provided by Teva Pharmaceuticals. NIOX VERO devices for measuring exhaled |
| 21 22 | 386 | nitric oxide were provided free of charge by Circassia Pharmaceuticals. |
| 23 24 25 | 387 | |
| 26 27 | 388 | Conflicts of Interest: |
| 28 29 | 389 | Elisabeth Callen: Dr. Callen receives support for other work (paid directly to her |
| 30 31 22 | 390 | institution) from Otsuka Pharmaceuticals, NIH, PCORI, HRSA, United Health |
| 32 33 34 | 391 | Foundation, SAMHSA, Merck, Eli Lilly, CDC, and Takeda. |
| 35 36 | 392 | Elliot Israel: Dr. Israel receives support for other work (paid directly to his institution) |
| 37 38 | 393 | from AstraZeneca, Avillion Mandala/Denali, Circassia, Gossamer Bio, NIH, Novartis, |
| 39 40 41 | 394 | and PCORI; he receives consulting fees from Allergy and Asthma Network, Amgen, |
| 42 43 | 395 | AstraZeneca, Avillion, GlaxoSmithKline, Merck, NHLBI, Novartis, Pneuma Respiratory, |
| 44 45 | 396 | Regeneron, Sanofi Genzyme, TEVA, and Cowen; he receives royalties from UpToDate |
| 46 47 48 | 397 | - Wolters Kluwer; he has been paid honoraria from TEVA, Cowen, and Westchester |
| 49 50 | 398 | Medical Center; he has been paid for expert testimony by Cambridge Medical Experts, |
| 51 52 | 399 | Danaher Lagnese, and SettlePou; he has been paid for Participation on a Data Safety |
| 53 54 55 | 400 | Monitoring Board or Advisory Board by Novartis; he is a member of the coordinating |
| 55 56 57 | | |
| 58 | | 00 |

committed for National Asthma Education Prevention Program and he is on the editorial board for the Journal of Allery and Clinical Immunology and the Journal of Allergy & Clinical Immunology, in Practice; he owns stock in Nesos Corp; and he has received a study drug for an unrelated study from Genentech, Sun Pharmaceuticals, Laurel Pharmaceuticals, Om Pharmaceuticals, Nestle, CSL Behring, Glaxo, and Sanofi Regeneron. Juan Carlos Cardet: Dr Cardet reports receiving honoraria from AstraZeneca, Chiesi, GSK, Genentech, and Sanofi for work on advisory boards and delivering lectures on asthma pathobiology and management. **Anne Fuhlbrigge:** Dr Fuhlbrigge an unpaid consultant to Teva, AstraZeneca and Novartis pharmaceuticals for epidemiologic analyses related to asthma outcomes and a co-investigator for the PREPARE, funded through PCORI. Gabriela Gaona: declares no conflict of interest. Wilson Pace: Dr. Pace's organization has received funding via subcontracts from CDC, PCORI, NIH, Boehringer Ingelheim, ONC, Tabula Rasa Healthcare, and Astra-Zeneca; his organization received consulting fees for his work from Boehringer Ingelheim; his organization has received payment for expert testimony; he is on the Advisory Board (paid) for AT Still Research Foundation and an Advisory board and Executive Committee member (unpaid) for COPD Foundation 360 Network; he owns stock through trust in Johnson and Johnson, Eli Lilly, Novo-Nordisk, Pfizer, Novartis, Moderna, and Amgen; he received grant and writing support for an unrelated project from Boehringer Ingelheim; and is an unpaid members of Colorado Medicaid Provider Rate Review Committee.

ur (ABES) . data mining, Al training, and similar technologies

| Brian Manning: declares no conflict of interest. | |
|---|----|
| Elizabeth Staton: declares no conflict of interest. | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| 2 For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml | 24 |

| 1 2 3 | 427 | References |
|----------------------------------|-----|--|
| 4 5 | 428 | |
| 6 7 8 | 429 | 1. Centers for Disease Control and Prevention. Asthma in the US 2011 [updated |
| 9 10 | 430 | May 3, 2011. Available from: <u>https://www.cdc.gov/vitalsigns/asthma/index.html</u> . |
| 11 12 13 | 431 | 2. Zahran HS, Bailey CM, Damon SA, Garbe PL, Breysse PN. Vital Signs: Asthma |
| 13 14 15 | 432 | in Children - United States, 2001-2016. MMWR Morb Mortal Wkly Rep. 2018;67(5):149- |
| 16 17 | 433 | 55. |
| 18 19 20 | 434 | 3. Healthy Schools Campaign. Five Health-Related Causes of Chronic |
| 21 22 | 435 | Absenteeism 2016 [updated August 29, 2016. Available from: |
| 23 24 | 436 | https://healthyschoolscampaign.org/blog/five-health-related-causes-of-chronic- |
| 25 26 27 | 437 | absenteeism/. |
| 28 29 | 438 | 4. McGregor MC, Krings JG, Nair P, Castro M. Role of Biologics in Asthma. Am J |
| 30 31 | 439 | Respir Crit Care Med. 2019;199(4):433-45. |
| 32 33 34 | 440 | 5. Institute for Clinical and Economic Review. Biologic Therapies for Treatment of |
| 35 36 | 441 | Asthma Associated with Type 2 Inflammation: Effectiveness, Value, and Value-Based |
| 37 38 | 442 | Price Benchmarks. Final Evidence Report 2018 [updated December 20, 2018. Available |
| 39 40 41 | 443 | from: https://icer.org/assessment/asthma-2018/. |
| 42 43 | 444 | 6. Peters M. Single-inhaler combination therapy for maintenance and relief of |
| 44 45 | 445 | asthma: a new strategy in disease management. Drugs. 2009;69(2):137-50. |
| 46 47 48 | 446 | 7. O'Byrne PM, Bisgaard H, Godard PP, Pistolesi M, Palmqvist M, Zhu Y, et al. |
| 49 50 | 447 | Budesonide/formoterol combination therapy as both maintenance and reliever |
| 51 52 | 448 | medication in asthma. Am J Respir Crit Care Med. 2005;171(2):129-36. |
| 53 54 55 56 57 58 | | |
| 59 60 | | For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml 25 |

Page 27 of 31

| 1 2 | | | | |
|----------------|-----|---------------|--|------|
| - 3 4 | 449 | 8. | Rabe KF, Pizzichini E, Stallberg B, Romero S, Balanzat AM, Atienza T, et al. | |
| 5 6 | 450 | Bude | sonide/formoterol in a single inhaler for maintenance and relief in mild-to-moder | rate |
| 7 8 9 | 451 | asthm | na: a randomized, double-blind trial. Chest. 2006;129(2):246-56. | |
| 9 10 11 | 452 | 9. | Scicchitano R, Aalbers R, Ukena D, Manjra A, Fouquert L, Centanni S, et al. | |
| 12 13 | 453 | Effica | acy and safety of budesonide/formoterol single inhaler therapy versus a higher | |
| 14 15 | 454 | dose | of budesonide in moderate to severe asthma. Curr Med Res Opin. | |
| 16 17 18 | 455 | 2004; | ;20(9):1403-18. | |
| 19 20 | 456 | 10. | Jenkins CR, Eriksson G, Bateman ED, Reddel HK, Sears MR, Lindberg M, | |
| 21 22 | 457 | O'Byr | rne PM. Efficacy of budesonide/formoterol maintenance and reliever therapy | |
| 23 24 25 | 458 | comp | pared with higher-dose budesonide as step-up from low-dose inhaled corticoster | oid |
| 25 26 27 | 459 | treatn | ment. BMC Pulm Med. 2017;17(1):65. | |
| 28 29 | 460 | 11. | Bisgaard H, Le Roux P, Bjamer D, Dymek A, Vermeulen JH, Hultquist C. | |
| 30 31 32 | 461 | Bude | sonide/formoterol maintenance plus reliever therapy: a new strategy in pediatric | 2 |
| 32 33 34 | 462 | asthm | na. Chest. 2006;130(6):1733-43. | |
| 35 36 | 463 | 12. | Global Initiative for Asthma. Global strategy for asthma management and | |
| 37 38 | 464 | preve | ention 2021 report. 2020 [Available from: <u>https://ginasthma.org/gina-reports/</u> . | |
| 39 40 41 | 465 | 13. | Global Initiative for Asthma. Difficult-to-treat and severe asthma in adolescent | |
| 42 43 | 466 | and a | adult patients. Diagnosis and management 2019 [Available from: | |
| 44 45 | 467 | <u>https:</u> | ://ginasthma.org/gina-reports/gina-2020-full-reportfinalwms. | |
| 46 47 48 | 468 | 14. | National Asthma Education and Prevention Program Coordinating Committee | |
| 49 50 | 469 | Expe | rt Panel Working Group. 2020 Focused Update to the Asthma Management | |
| 51 52 | 470 | Guide | elines Summary from: A Report from the National Asthma Education and | |
| 53 54 55 | 471 | Preve | ention Program Coordinating Committee Expert Panel Working Group 2020 | |
| 55 56 57 | | | | |
| 58 59 | | | | 26 |
| 60 | | | For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml | |

| 2 3 | 472 | [Available from: https://www.nhlbi.nih.gov/health-topics/all-publications-and- |
|----------------|-----|--|
| 4 5 6 | 473 | resources/2020-focused-updates-asthma-management-guidelines. |
| 7 8 | 474 | 15. Centers for Disease Control and Prevention. Asthma Attacks in the Past 12 |
| 9 10 11 | 475 | Months by Year 2019 [Available from: https://www.cdc.gov/asthma/data- |
| 12 13 | 476 | visualizations/health-outcomes.htm#anchor_1569609411376. |
| 14 15 | 477 | 16. Centers for Disease Control and Prevention. Asthma Attacks among People with |
| 16 17 18 | 478 | Current Asthma, 2014–2017 2019 [Available from: |
| 18 19 20 | 479 | https://www.cdc.gov/asthma/asthma_stats/attacks-current-asthma.htm. |
| 21 22 | 480 | 17. Moorman JE, Akinbami LJ, Bailey CM, Zahran HS, King ME, Johnson CA, Liu X. |
| 23 24 25 | 481 | National surveillance of asthma: United States, 2001-2010. Vital Health Stat 3. |
| 25 26 27 | 482 | 2012(35):1-58. |
| 28 29 | 483 | 18. Cardet JC, Chang KL, Rooks BJ, Carroll JK, Celedon JC, Coyne-Beasley T, et |
| 30 31 32 | 484 | al. Socioeconomic status associates with worse asthma morbidity among Black and |
| 33 34 | 485 | Latinx adults. J Allergy Clin Immunol. 2022. |
| 35 36 | 486 | 19. Cardet JC, Shenoy K, Baydur A, Carroll JK, Celedon JC, Cui J, et al. Caribbean |
| 37 38 | 487 | Latinx with Moderate-Severe Asthma Bear Greater Asthma Morbidity than Othe Latinx. |
| 39 40 41 | 488 | Journal of Allergy and Clinical Immunology. 2022;150(5):1106-13. |
| 42 43 | 489 | 20. Szentpetery SE, Forno E, Canino G, Celedón JC. Asthma in Puerto Ricans: |
| 44 45 | 490 | Lessons from a high-risk population. J Allergy Clin Immunol. 2016;138(6):1556-8. |
| 46 47 48 | 491 | 21. Bartolomei-Díaz JA, Amill-Rosario A, Claudio L, Hernández W. Asthma mortality |
| 49 50 | 492 | in Puerto Rico: 1980-2007. J Asthma. 2011;48(2):202-9. |
| 51 52 | | |
| 53 54 55 | | |
| 56 57 | | |
| 58 59 60 | | 27 For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml |
| 00 | | |

| 1 2 | | | | |
|----------------|-----|---------------|---|-----------|
| - 3 4 | 493 | 22. | British Thorasic Society. BTS/SIGN British Guideline on the Management of | |
| 5 6 7 | 494 | Asthm | na 2021 [updated 12/2021. Available from: <u>https://www.brit-thoracic.org.uk/quality</u> | <u>y-</u> |
| 7 8 9 | 495 | <u>improv</u> | vement/guidelines/asthma/ | |
| 10 11 | 496 | 23. | Boushey HA, Sorkness CA, King TS, Sullivan SD, Fahy JV, Lazarus SC, et al. | |
| 12 13 | 497 | Daily | versus as-needed corticosteroids for mild persistent asthma. N Engl J Med. | |
| 14 15 16 | 498 | 2005; | 352(15):1519-28. | |
| 17 18 | 499 | 24. | Papi A, Canonica GW, Maestrelli P, Paggiaro P, Olivieri D, Pozzi E, et al. Resci | ue |
| 19 20 | 500 | use of | f beclomethasone and albuterol in a single inhaler for mild asthma. N Engl J Med | ١. |
| 21 22 | 501 | 2007; | 356(20):2040-52. | |
| 23 24 25 | 502 | 25. | Calhoun WJ, Ameredes BT, King TS, Icitovic N, Bleecker ER, Castro M, et al. | |
| 26 27 | 503 | Comp | parison of physician-, biomarker-, and symptom-based strategies for adjustment o | of |
| 28 29 | 504 | inhale | ed corticosteroid therapy in adults with asthma: the BASALT randomized controlle | ed |
| 30 31 32 | 505 | trial. J | IAMA. 2012;308(10):987-97. | |
| 32 33 34 | 506 | 26. | Rabe KF, Atienza T, Magyar P, Larsson P, Jorup C, Lalloo UG. Effect of | |
| 35 36 | 507 | budes | sonide in combination with formoterol for reliever therapy in asthma exacerbation | S: |
| 37 38 | 508 | a ranc | domised controlled, double-blind study. Lancet. 2006;368(9537):744-53. | |
| 39 40 41 | 509 | 27. | Miller NH. Compliance with treatment regimens in chronic asymptomatic | |
| 42 43 | 510 | diseas | ses. The American Journal of Medicine. 1997;102(2A):43-9. | |
| 44 45 | 511 | 28. | Haynes RB, Ackloo E, Sahota N, McDonald HP, Yao X. Interventions for | |
| 46 47 49 | 512 | enhar | ncing medication adherence. Cochrane Database Syst Rev. 2008(2):CD000011. | |
| 48 49 50 | 513 | 29. | Papi A, Corradi M, Pigeon-Francisco C, Baronio R, Siergiejko Z, Petruzzelli S, e | ət |
| 51 52 | 514 | al. Be | clometasone-formoterol as maintenance and reliever treatment in patients with | |
| 53 54 | | | | |
| 55 56 | | | | |
| 57 58 | | | | 00 |
| 59 | | | | 28 |

| 1 2 | | |
|----------------|-----|---|
| 3 4 | 515 | asthma: a double-blind, randomised controlled trial. Lancet Respir Med. 2013;1(1):23- |
| 5 6 7 | 516 | 31. |
| 7 8 9 | 517 | 30. Israel E, Cardet JC, Carroll JK, Fuhlbrigge AL, She L, Rockhold FW, et al. |
| 9 10 11 | 518 | Reliever-Triggered Inhaled Glucocorticoid in Black and Latinx Adults with Asthma. N |
| 12 13 | 519 | Engl J Med. 2022. |
| 14 15 16 | 520 | 31. Israel E, Cardet JC, Carroll JK, Fuhlbrigge AL, Pace WD, Maher NE, She L. A |
| 10 17 18 | 521 | randomized, open-label, pragmatic study to assess reliever-triggered inhaled |
| 19 20 | 522 | corticosteroid in African American/Black and Hispanic/Latinx adults with asthma: design |
| 21 22 | 523 | and methods of the PREPARE trial. Contemporary Clinical Trials. 2021;101, 106246. |
| 23 24 25 | 524 | 32. Definition and DDLs for the OMOP Common Data Model (CDM) 2022 [updated |
| 26 27 | 525 | Auguest, 2022. Available from: https://github.com/OHDSI/CommonDataModel. |
| 28 29 | 526 | 33. Linear Mixed Models in Practice: A SAS-Oriented Approach: Springer Science & |
| 30 31 | 527 | Business Media; 2012. |
| 32 33 34 | 528 | 34. Garcia TP, Marder K. Statistical Approaches to Longitudinal Data Analysis in |
| 35 36 | 529 | Neurodegenerative Diseases: Huntington's Disease as a Model. Current Neurology and |
| 37 38 | 530 | Neuroscience Reports. 2017;17(2):14. |
| 39 40 41 | 531 | 35. Raudenbush SW, Bryk AS. Hierarchical Linear Models: Applications and Data |
| 42 43 | 532 | Analysis Methods. 2nd ed. Thousand Oaks, CA: Sage Publications; 2002. |
| 44 45 | 533 | 36. Salciccioli JD, She L, Tulchinsky A, Rockhold F, Cardet JC, Israel E. Effect of |
| 46 47 49 | 534 | COVID-19 on asthma exacerbation. J Allergy Clin Immunol Pract. 2021;9(7):2896-9.e1. |
| 48 49 50 | 535 | 37. American Academy of Asthma al. Asthma IQ: patient management and |
| 51 52 | 536 | outcomes [Available from: https://education.aaaai.org/AIQMgmtOutcomes. |
| 53 54 | 537 | |
| 55 56 | | |
| 57 58 | | |
| 59 60 | | For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml |

| 1 | | |
|----------|----------|--|
| 2 | | |
| 3 4 | 1 | Supplemental Materials |
| 5 | 2 | |
| 6 | 3 | Hierarchy of Controller Step Levels |
| 7 | 4 | |
| 8 | 5 | Step 2 |
| 9 | 6 | ○ Low dose ICS |
| 10 | 7 | • Step 3 |
| 11 | 8 | Low dose ICS plus Leukotriene inhibitor |
| 12 | 9 | Medium dose ICS |
| 13 | 10 | Low dose ICS plus LABA OR LAMA |
| 14 | 11 | • High dose ICS |
| 15 | 12 | • Step 4 |
| 16 17 | 13 | Medium dose ICS plus Leukotriene inhibitor |
| 18 | 14 | Low dose ICS plus LABA OR LAMA plus Leukotriene inhibitor |
| 19 | 15 | Low dose ICS plus LABA AND LAMA Low dose ICS plus LABA AND LAMA plus Low/astriang inhibitor |
| 20 | 16 | Low dose ICS plus LABA AND LAMA plus Leukotriene inhibitor High dose ICS plus Laukotriene inhibitor |
| 21 | 17 | High dose ICS plus Leukotriene inhibitor Madium dose ICS plus LABA OB LAMA |
| 22 | 18 10 | Medium dose ICS plus LABA OR LAMA Medium dose ICS plus LABA OR LAMA plus Louketrians inhibitor |
| 23 | 19 | Medium dose ICS plus LABA OR LAMA plus Leukotriene inhibitor |
| 24 | 20 | Step 5 |
| 25 | 21 | Medium dose ICS plus LABA AND LAMA Medium dose ICS plus LABA AND LAMA plus Louketriops inhibitor |
| 26 | 22 23 | Medium dose ICS plus LABA AND LAMA plus Leukotriene inhibitor High dose ICS plus LABA OB LAMA |
| 27 | 23 24 | High dose ICS plus LABA OR LAMA High dose ICS plus LABA AND LAMA |
| 28 | 24 25 | |
| 29 | 26 | |
| 30 31 | 20 27 | High dose ICS plus LABA AND LABA plus Leukotriene inhibitor Step 6 |
| 32 | 28 | |
| 33 | 29 | Biologics Daily Corticosteroids |
| 34 | 30 | o Daily conticosteroids |
| 35 | 31 | Overall Model for All 28 Months (Supplemental Table 1; no corrections applied; no spline) |
| 36 | 32 | |
| 37 | 33 | The month before or after enrollment did show a significant increase over time (estimate: 0.039; |
| 38 | 34 | t = 9.315). The UCare patients were at a significantly higher asthma controller medication level |
| 39 | 35 | overall (difference: 0.191 ; t = 2.327). The assigned reclassified levels differed significantly |
| 40 | 36 | between the sites (F(15, 692.810) = 19.968; p = 0.000). Five sites (Sites 2, 3, 4, 5, 7) had |
| 41 | 37 | significantly higher steps of asthma controller medications than patients from Site 16. Two sites |
| 42 | 38 | (Sites 6, 15) had significantly lower steps of asthma controller medications than patients from |
| 43 44 | 39 | Site 16. The assigned reclassified levels differed significantly with the patients' decade of birth |
| 44 45 | 40 | (F(4, 692.014) = 5.135; p = 0.000). Patients born in the 1940s/1950s had significantly higher |
| 46 | 41 | levels of asthma controller medications than patients born in the 1990s/2000s (difference: |
| 47 | 42 | 0.611; t = 3.803). Lastly, in the months were COVID-19 was not present (before April 2020), the |
| 48 | 43 | patients had a significantly higher asthma controller medication level than after the COVID-19 |
| 49 | 44 | pandemic began (difference: 0.902; t = 14.118; Supplemental Table 1). |
| 50 | 45 | |
| 51 | 46 | |
| 52 | | |
| 53 | | |
| 54 | | |
| 55 | | |
| 56 | | |
| 57 | | |
| 58 | | |
| 59 60 | | 1 For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml |
| 60 | | |

| Supplemental Table 1. Fin Parameter | Estimate | Standard Error | 95% CI | t | | |
|--|---------------|---------------------|-------------------------------|----------------------|--|--|
| | | | | | | |
| -2 Restricted Log Likelihood: 73628.74 Month: F(1, 740.37) = 86.77; p < 0.001 | | | | | | |
| Group: $F(1, 691.99) = 5.41; p = 0.02$ | | | | | | |
| Site: F(15, 692.81) = 19.97; p < 0.001 | | | | | | |
| Decade of Birth: F(4, 692.01) = 5.14; p < 0.001 | | | | | | |
| | | l, 18759.68) = 199. | | | | |
| Intercept (Baseline) | 0.78 | 0.24 | [0.31, 1.25] | 3.24* | | |
| Month | 0.04 | 0.00 | [0.03, 0.05] | 9.32* | | |
| UCare | 0.19 | 0.08 | [0.03, 0.35] | 2.33* | | |
| PARTICS | Reference | | | | | |
| Site 1 Site 2 | -0.44 1.14 | 0.34 | [-1.11, 0.24] [0.55, 1.73] | -1.27 3.80* | | |
| Site 3 | 1.14 | 0.23 | [1.05, 1.96] | 6.49* | | |
| Site 3 | 0.91 | 0.23 | [0.40, 1.42] | 3.49* | | |
| Site 5 | 1.22 | 0.23 | [0.76, 1.68] | 5.24* | | |
| Site 6 | -0.93 | 0.22 | [-1.36, -0.50] | -4.25* | | |
| Site 7 | 0.66 | 0.22 | [0.23, 1.08] | 3.02* | | |
| Site 8 | 0.04 | 0.33 | [-0.61, 0.69] | 0.13 | | |
| Site 9 | 0.27 | 0.24 | [-0.21, 0.74] | 1.11 | | |
| Site 10 | 0.05 | 0.23 | [-0.41, 0.50] | 0.19 | | |
| Site 11 | 0.11 | 0.25 | [-0.38, 0.60] | 0.43 | | |
| Site 12 | -0.24 | 0.41 | [-1.04, 0.57] | -0.58 | | |
| Site 13 | -0.07 | 0.23 | [-0.51, 0.37] | -0.33 | | |
| Site 14 | 0.17 | 0.23 | [-0.27, 0.62] | 0.78 | | |
| Site 15 | -1.43 | 0.35 | [-2.13, -0.74] | -4.05* | | |
| Site 16 | 0.61 | Refer | | 2.00* | | |
| Born: 1940s & 1950s Born: 1960s | 0.61 | 0.16 | [0.30, 0.93] [-0.11, 0.52] | <u>3.80*</u> 1.29 | | |
| Born: 1970s | 0.21 | 0.10 | [-0.07, 0.58] | 1.54 | | |
| Born: 1980s | 0.31 | 0.17 | [-0.03, 0.65] | 1.80+ | | |
| Born: 1990s & 2000s | Reference | | | | | |
| No COVID-19 | 0.90 | 0.06 | [0.78, 1.03] | 14.19* | | |
| COVID-19 Present | | Refer | | | | |
| p-value < 0.05 | | | | | | |
| • | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |

An electronic health record data analysis on the impact of rescue triggered inhaled corticosteroids on controller therapy in Black and Latinx Individuals from a pragmatic, open label, patient level randomized trial

| Journal: | BMJ Open |
|--------------------------------------|--|
| Manuscript ID | bmjopen-2024-088349.R1 |
| Article Type: | Original research |
| Date Submitted by the Author: | 23-Sep-2024 |
| Complete List of Authors: | Callen, Elisabeth; American Academy of Family Physicians; DARTNet Institute Israel, Elliot; Brigham and Women's Hospital, Division of Pulmonary and Critical Care Medicine and Division of Allergy and Immunology Cardet, Juan Carlos; University of South Florida, Morsani College of Medicine, Division of Allergy and Immunology, Department of Internal Medicine Fuhlbrigge, Anne L ; University of Colorado School of Medicine, Pulmonary Science and Critical Care Medicine, Department of Medicine Manning, Brian; American Academy of Family Physicians; DARTNet Institute Gaona, Gabriela; DARTNet Institute Staton, Elizabeth; DARTNet Institute; University of Colorado Anschutz Medical Campus School of Medicine, Department of Family Medicine Pace, Wilson; DARTNet Institute |
| Primary Subject Heading : | Ear, nose and throat/otolaryngology |
| Secondary Subject Heading: | Epidemiology, Health informatics |
| Keywords: | Patients, Asthma < THORACIC MEDICINE, STATISTICS & RESEARCH METHODS |
| | |

SCHOLARONE[™] Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our <u>licence</u>.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which <u>Creative Commons</u> licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

terez oni

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies



| 2 | | | | | |
|----------------------|----|---|--|--|--|
| 3 4 | 1 | An electronic health record data analysis on the impact of rescue triggered inhaled | | | |
| 5 6 | 2 | corticosteroids on controller therapy in Black and Latinx Individuals from a pragmatic, | | | |
| 7 8 9 | 3 | open label, patient level randomized trial | | | |
| 9 10 11 | 4 | | | | |
| 12 13 | 5 | Elisabeth F. Callen, PhD ^{1,2*} , Elliot Israel, MD ³ , Juan Carlos Cardet, MD, MPH ⁴ , Anne | | | |
| 14 15 | 6 | L. Fuhlbrigge, MD, MS ⁵ , Brian K. Manning, MPH ^{1,2} , Gabriela Gaona, MPH, CPH ² , | | | |
| 16 17 18 | 7 | Elizabeth W. Staton, MSTC ^{2,6} , Wilson D. Pace, MD, FAAFP ² | | | |
| 19 20 | 8 | ¹ American Academy of Family Physicians National Research Network, Leawood, | | | |
| 21 22 | 9 | Kansas, United States of America | | | |
| 23 24 | 10 | ² DARTNet Institute, Aurora, Colorado, United States of America | | | |
| 25 26 27 | 11 | ³ Division of Pulmonary and Critical Care Medicine and Division of Allergy and | | | |
| 28 29 30 31 | 12 | Immunology, Brigham and Women's Hospital, Boston, Massachusetts, United States of | | | |
| | 13 | America | | | |
| 32 33 34 | 14 | ⁴ Division of Allergy and Immunology, Department of Internal Medicine, University of | | | |
| 35 36 37 38 | 15 | South Florida, Morsani College of Medicine, Tampa, Florida, United States of America | | | |
| | 16 | ⁵ Pulmonary Science and Critical Care Medicine, Department of Medicine, University of | | | |
| 39 40 41 | 17 | Colorado School of Medicine, Aurora, Colorado, United States of America | | | |
| 42 43 | 18 | ⁶ University of Colorado Department of Family Medicine, Aurora, Colorado, United | | | |
| 44 45 | 19 | States of America | | | |
| 46 47 48 | 20 | | | | |
| 49 50 | 21 | *Corresponding Author: | | | |
| 51 52 | 22 | Email: elisabeth.callen@dartnet.info | | | |
| 53 54 | 23 | | | | |
| 55 56 | 24 | | | | |
| 57 58 | | | | | |
| 59 60 | | 1 For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml | | | |

Page 3 of 31

BMJ Open

| 25 | Abstract |
|----|--|
| 26 | Objective: The Person Empowered Asthma Relief (PREPARE) study found that as- |
| 27 | needed inhaled corticosteroid supplementation combined with participants' usual |
| 28 | controller and rescue therapy reduced asthma exacerbations for Black and Latinx |
| 29 | individuals. Here we sought to determine if treatment assignment to the Intervention |
| 30 | (called PARTICS) vs Control (Usual Care) had an impact on controller therapy based on |
| 31 | clinicians' written prescriptions. Design: Secondary data analysis of electronic health |
| 32 | record data of a pragmatic, open label, patient level randomized trial. Setting: Practices |
| 33 | treating asthma. Participants: PREPARE study participants - Black and Latinx |
| 34 | individuals with asthma. Interventions: Effects of adding ICS to rescue therapy among |
| 35 | Black and Hispanic adults with moderate-to-severe asthma. Outcome Measures: For |
| 36 | PARTICS therapy impact on patients, each month is the 28-month period (12 months |
| 37 | prior to enrollment, the month of enrollment, and 15 months after enrollment), a patient |
| 38 | was assigned to a controller step based on a 6-step classification scheme. A Linear |
| 39 | Mixed Effect Spline Model was completed for before and after enrollment data to |
| 40 | determine controller changes over a 28-month period between the two study arms. |
| 41 | Results: This analysis included 713 participants. Of these, 49.1% were Usual Care |
| 42 | patients and 50.9% were PARTICS patients. Throughout the study, the majority of |
| 43 | patients changed asthma controller medications in both arms. By the end of the study, |
| 44 | the Usual Care patients were at a significantly higher asthma controller medication step |
| 45 | (0.20 step higher) than the PARTICS patients. Conclusions: Clinicians' prescribing |
| 46 | patterns showed significant changes over time. Compared with Usual Care patients, |
| | |

PARTICS patients were on lower doses of asthma controller medications by the end of

| 2 | |
|----------|----|
| 3 | 47 |
| 4 5 | 48 |
| 6 7 | 40 |
| 8 9 | 49 |
| 10 | |
| 11 12 | |
| 13 14 | |
| 15 16 | |
| 17 | |
| 18 19 | |
| 20 21 | |
| 22 | |
| 23 24 | |
| 25 26 | |
| 27 | |
| 28 29 | |
| 30 31 | |
| 32 | |
| 33 34 | |
| 35 36 | |
| 37 | |
| 38 39 | |
| 40 41 | |
| 42 | |
| 43 44 | |
| 45 46 | |
| 47 | |
| 48 49 | |
| 50 51 | |
| 52 | |
| 53 54 | |
| 55 56 | |
| 56 57 | |

58 59

60

the study.

to perteries only

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

| 1 2 | | |
|----------------|----|--|
| 2 3 4 | 50 | Strengths and Limitations of This Study: |
| 5 6 | 51 | Strength: Long follow-up time using electronic health record analysis of |
| 7 8 9 | 52 | controller medications prescribed from 12 months before enrollment into the |
| 9 10 11 | 53 | Person Empowered Asthma Relief (PREPARE) study through 15 months after |
| 12 13 | 54 | enrollment. |
| 14 15 16 | 55 | • Strength: Even if data were missing, we were able to use all available data due to |
| 17 18 | 56 | the type of analysis we used – Linear Mixed Effect Model. |
| 19 20 | 57 | Limitation: EHR data have inherent missingness and can have gaps due to |
| 21 22 23 | 58 | infrequent visits and prescribing activities. |
| 23 24 25 | 59 | Limitation: Some individuals were on dual ICS inhalers not counting the study- |
| 26 27 | 60 | prescribed beclomethasone, and these individuals were assigned based on the |
| 28 29 30 | 61 | highest potency of any of the non-study prescribed ICS inhalers. |
| 31 32 | 62 | Limitation: In addition, not every site within PREPARE provided data, but we had |
| 33 34 | 63 | data from the majority of sites. |
| 35 36 37 | | |
| 37 38 39 | | |
| 40 41 | | |
| 42 43 44 | | |
| 44 45 46 | | |
| 47 48 | | |
| 49 50 | | |
| 51 52 53 | | |
| 54 55 | | |
| 56 57 | | |
| 58 59 60 | | For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml |

64 INTRODUCTION

Twenty-five million adults have asthma in the US.¹ Asthma exacerbations cause the largest number of lost days (one-third of all days) from school or work for children and young adults.²³ Despite new medications,⁴⁵ new drug regimens,⁶⁻¹¹ and the ongoing evolution of treatment guidelines¹²⁻¹⁴, the number of people with asthma exacerbations in the previous year has decreased only slightly over the past 20 years, from 51.6% to 46.0%.^{15 16} Asthma is also a disease with a high degree of disparities in outcomes. Black individuals have exacerbation and death rates that are 2-2.5 times higher than White individuals and Asian individuals,¹⁷ while Hispanic individuals, particularly Caribbean Hispanic individuals,¹⁸¹⁹ have 2 times the rate of exacerbations and 1.5 times the death rate.^{20 21} Thus, there is an ongoing need to expand and improve treatment approaches for individuals with asthma.

The paradigm concerning use of inhaled corticosteroids (ICS) only as a controller, i.e., as a once or twice a day medication, has been evolving. The use of ICS-formoterol as both controller and rescue therapy (single maintenance and reliever therapy [SMART]) is endorsed by multiple guideline groups across the world, include the US, GINA, and UK guidelines.^{12 14 22} Previous randomized controlled trials have also demonstrated that as-needed, stand-alone, ICS use in conjunction with short acting beta-agonist (SABA) for acute asthma symptom relief can improve asthma outcomes.^{7 23-29} The Person Empowered Asthma Relief (PREPARE) trial utilized a stand-alone ICS combined with participants' usual controller and rescue therapy in an approach called Patient Activated Reliever-Triggered ICS (PARTICS).³⁰

BMJ Open

| 1 | |
|----------------|-----|
| 2 3 | 87 |
| 4 5 | 07 |
| 6 | 88 |
| 7 8 | 89 |
| 9 10 | |
| 11 | 90 |
| 12 13 | 91 |
| 14 15 16 | 92 |
| 10 17 18 | 93 |
| 19 20 | 94 |
| 21 22 | 95 |
| 23 24 25 | 96 |
| 25 26 27 | 97 |
| 28 29 | 98 |
| 30 31 | 99 |
| 32 33 34 | 100 |
| 34 35 36 | 101 |
| 37 38 | 102 |
| 39 40 | 103 |
| 41 42 | 104 |
| 43 44 45 | 105 |
| 46 47 | 106 |
| 48 49 | 107 |
| 50 51 | |
| 52 | 108 |
| 53 54 | 109 |
| 55 56 | |
| 57 | |
| 58 59 | |
| 60 | |

87 The PARTICS intervention in PREPARE decreased asthma exacerbations, improved 88 asthma control and guality of life, and reduced reliever use in African American/Black 89 (AA/B) and Hispanic/Latinx (H/L) adults with moderate to severe asthma, a group with 90 disproportionate asthma morbidity that has been difficult to reduce.³⁰ This research 91 92 extended the general concept of using ICS with all rescue beta-agonist use, whether long- or short-acting. It also demonstrated effectiveness, through changes in validated 93 assessments, in AA/B and H/L adults, integrated with rescue nebulizer therapy, required 94 no changes in a participant's current controller therapy, and appears to have fewer 95 insurance barriers than an ICS-formoterol based approach. Participants on PARTICS 96 also reported lower SABA use, both as a metered dose inhaler and via nebulizer, and 97 fewer controller refills as well as a self-reported reduction in controller ICS dosage.³⁰ 98 99 The objective of this paper is to report on a pre-specified PREPARE trial sub-analysis 100 using electronic health record (EHR) data to determine if treatment assignment (the 101 PARTICS intervention vs. usual care) had an impact on controller therapy through 102

103 clinicians' written prescriptions. The analysis compares changes in controller intensity (e.g., low, medium, or high ICS dose) as determined by EHR data over a 28-month 104 105 period (12 months prior to enrollment, month of enrollment, and 15 months after 106 enrollment) between the two arms of the study.

- - 108 METHODS
- 109

6

BMJ Open: first published as 10.1136/bmjopen-2024-088349 on 21 November 2024. Downloaded from http://bmjopen.bmj.com/ on June 13, 2025 at Agence Bibliographique de Enseignement Superieur (ABES)

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies

| 1 | |
|---|--|
| 2 | |
| 3 4 5 | |
| 4 | |
| 5 | |
| 6 | |
| 7 | |
| / | |
| 8 | |
| 9 | |
| 10 | |
| 11 | |
| 12 | |
| 13 | |
| 14 | |
| 15 | |
| 16 | |
| 17 | |
| 10 | |
| 10 | |
| 6 7 8 9 10 12 13 14 15 16 17 18 20 21 23 24 25 26 27 28 30 312 33 34 35 36 37 | |
| 20 | |
| 21 | |
| 22 | |
| 23 | |
| 24 | |
| 25 | |
| 26 | |
| 27 | |
| 20 | |
| 20 | |
| 29 | |
| 30 | |
| 31 | |
| 32 | |
| 33 | |
| 34 | |
| 35 | |
| 36 | |
| 37 | |
| 38 | |
| 39 | |
| 39 40 | |
| | |
| 41 | |
| 42 | |
| 43 | |
| 44 | |
| 45 | |
| 46 | |
| 47 | |
| 48 | |
| 49 | |
| 50 | |
| 50 51 | |
| 51 | |
| | |
| 53 | |
| 54 | |
| 55 | |
| 56 | |
| 57 | |
| 58 | |
| 50 | |

110

111

Brief Description of the PREPARE Study

The PREPARE study was a pragmatic, open label, patient level randomized trial 112 designed to observe the effects of adding ICS to rescue therapy among AA/B and H/L 113 adults with moderate-to-severe asthma.³¹ In the PREPARE study, the 114 Intervention/PARTICS group (hereafter, "PARTICS group") received additional ICS 115 medication (donated by TEVA, beclomethasone 80 mcg) and was asked to use 1 puff of 116 beclomethasone for every 1 puff of usual rescue inhaler and 5 puffs of beclomethasone 117 for every 1 rescue nebulization, in addition to usual care. The control group received 118 usual care (hereafter, "UCare group"), described previously.³¹ Exacerbations were 119 tracked using patient-reported outcomes that were adjudicated using EHR data and 120 patient interviews. The sub-study detailed here covers the prescriber side of asthma 121 controller medications, as recorded in the EHRs of the primary asthma treating clinician 122 (primary care, pulmonologist or allergist) for a subset of enrollees. To determine the 123 effect, we analyzed PREPARE participants' asthma controller medications over 28 124 months (12 months before enrollment into PREPARE, month of enrollment into 125 126 PREPARE, and 15 months after enrollment). The PREPARE study and this sub-study were approved by the IRB (Partners Human Research Committee: 2016P001839/BWH) 127 128 and written informed consent was obtained from each participant at the time of 129 enrollment (recruitment period: November 2017 – April 2021). 130 **EHR Data Acquisition** 131

132

Each site was asked to provide EHR data for each participant within the PREPARE study. The DARTNet Institute provided a set of instructions for each site including the variables needed from the EHR. Sixteen of the 19 participating sites provided data from their EHR or data warehouse. Requested information included care site information, patient visits, medications, diagnostic codes, and procedures. Each participating site provided a pilot data pull that was standardized to the Observational Medical Outcomes Partnership Common Data Model v5.4 (OMOP CDM v5.4) and reviewed for data quality. Data quality concerns were communicated back to the sites; in some cases, new data were submitted. After all patients from a given site had exited the study, that site re-pulled their data and sent it to DARTNet for data standardization. (Note: One site, Site 6, did not provide data for their patients from before their enrollment into CLICZ PREPARE.)

EHR Data Standardization

DARTNet utilized its standard procedures (python scripts and SQL coding) to transform the data received from each site into the OMOP CDM v5.4.32 Briefly, data were loaded into a receiving database. As data were moved into the final OMOP data model, known taxonomies were auto-mapped to source OMOP concept IDs and a "standard" OMOP concept ID. Source data using idiosyncratic codes were hand-mapped and processed through to the OMOP data model. Data quality reports were evaluated for all relevant sets of conditions, medications, procedures, and measures. Final data were sent to the American Academy of Family Physicians (AAFP) for cleaning and analysis.

| 1 | | |
|----------------------------|-----|--|
| 2 3 4 | 156 | |
| 5 6 7 | 157 | EHR Data Cleaning |
| , 8 9 | 158 | |
| 10 11 | 159 | Once the standardized data were received from DARTNet, the individual site files were |
| 12 13 | 160 | combined for analysis. DARTNet worked with the AAFP to review and modify, if |
| 14 15 16 | 161 | needed, existing "value sets" (i.e., list of codes associated with clinical concepts- either |
| 17 18 | 162 | specific medications, conditions, or procedures). Value sets were created that |
| 19 20 | 163 | segregated asthma medications as specifically needed for this analysis. Medications |
| 21 22 23 | 164 | were categorized on a monthly basis as active using the following rules: |
| 24 25 | 165 | Start date of medication: The month the prescription was written was considered |
| 26 27 | 166 | the start date/month. |
| 28 29 30 | 167 | End date of medication: |
| 30 31 32 | 168 | \circ If an end date was provided, then it was used if it was 12 months or less |
| 33 34 | 169 | from the time the prescription was written. |
| 35 36 27 | 170 | \circ If no end date was provided, then an end date of 12 months after the |
| 37 38 39 | 171 | prescription was written was used. |
| 40 41 | 172 | Dosage/quantity and refills provided were also used to determine if a 12-month |
| 42 43 | 173 | end date was appropriate or a shorter time span should be used due to how the |
| 44 45 46 | 174 | prescription was written. |
| 47 48 | 175 | Once each asthma medication for each patient had assigned months, all medications |
| 49 50 | 176 | were assigned to types of asthma medications (e.g., low/medium/high dose ICS, Long- |
| 51 52 53 | 177 | Acting Beta-Agonists (LABA), Long-Acting Muscarinic Antagonist (LAMA)). Using those |
| 54 55 56 57 58 | 178 | assigned types, all medications for each patient were collapsed into one record for each |

59

Page 11 of 31

60

BMJ Open

| 1 2 | | | |
|----------------|-----|--|---|
| 2 3 4 | 179 | month (patient-month). The medication types for each month were assigned to a | |
| 5 6 7 | 180 | controller step based on highest ICS dose (i.e., low, medium, high) that they were | |
| 7 8 9 | 181 | prescribed along with additional controller medications. | |
| 10 11 | 182 | | |
| 12 13 | 183 | Outcome Groupings | |
| 14 15 16 | 184 | | |
| 17 18 | 185 | Each patient-month was assigned to a controller step based on a six-step classification | |
| 19 20 21 | 186 | scheme. The hierarchy of controller step levels (located in Supplemental Materials) was | 3 |
| 21 22 23 | 187 | based on Guideline Steps (hereafter referred to as step) outlined in the National Asthma | а |
| 24 25 | 188 | Education and Prevention Program (NAEPP) guidelines. ¹⁴ If a patient had no | |
| 26 27 20 | 189 | medication used within the classification scheme, then the patient was assigned a "0" | |
| 28 29 30 | 190 | for the month indicating the patient had no asthma controller medications prescribed to | |
| 31 32 | 191 | him/her within a given month. The six-step classification scheme (plus "0" for no | |
| 33 34 | 192 | medication) was used as the dependent variable in the statistical models. | |
| 35 36 37 | 193 | | |
| 37 38 39 | 194 | Statistical Methods | |
| 40 41 | 195 | | |
| 42 43 | 196 | This analysis was a secondary data analysis. Descriptive and inferential statistics were | |
| 44 45 46 | 197 | completed as appropriate. To start, changes in asthma controller medication were | |
| 47 48 | 198 | determined by the starting and stopping of prescriptions according to the EHR data | |
| 49 50 | 199 | rules. A change was the movement up or down in the step hierarchy. Then to model the | |
| 51 52 53 | 200 | EHR data, Linear Mixed Effect Model (LME; overall model and a spline version) were | |
| 54 55 56 | 201 | used with the assigned asthma controller medication step in each month as the | |
| 57 58 59 | | 1 | 0 |

Page 12 of 31 BMJ Open: first published as 10.1136/bmjopen-2024-088349 on 21 November 2024. Downloaded from http://bmjopen.bmj.com/ on June 13, 2025 at Agence Bibliographique de Enseignement Superieur (ABES)

Protected by copyright, including for uses related to text

tand

ur (ABES) . data mining, Al training, and similar technologies

BMJ Open

dependent variable; independent variable(s) varied depending on the model. A series of LMEs were completed to determine the individual demographic variables that contributed (p < 0.05) to the model. The dependent variable for all LMEs was the six-step classification scheme described above. If a demographic variable contributed significantly (p<0.05) to an LME containing month, group, site, and that demographic variable, then the variable was included in the final models discussed below. We also included a COVID-19 correction variable to account for any possible changes in asthma controller medications that occurred due to the COVID-19 pandemic (i.e., 0=No COVID-19 pandemic present; 1=COVID-19 pandemic present). For each variable included in the LMEs, the final category (e.g., Site 16 out of Sites 1-16) was used as a reference category. LMEs require a reference category for each categorical variable as a comparison for the other categories. Due to the nature of the data and the autocorrelation present, the covariance matrix used was a Heterogeneous First-Order Autoregressive to account for the previous month's influence. LMEs were used due to the ability to cluster to the person/patient, the acceptance of potentially missing data, and that it also works for data that violate any distributional assumptions.³³⁻³⁵ An overall LME was completed for all 28 months of data (located in the Supplemental Materials) and a LME with Spline was completed for before and after enrollment data. For the final LMEs, the random variable was the intercept, clustered to the patient. The fixed variables were patient-month, group (PARTICS/UCare), site, decade of birth, and COVID-19 correction. An alpha of 0.05 was used. All analyses were completed using SAS 9.4 (Cary, NC).

226

227

RESULTS

Demographics

| 1 | |
|----------|--|
| 2 | |
| 3 | |
| 4 | |
| 4 5 | |
| | |
| 6 7 | |
| | |
| 8 | |
| 9 | |
| 10 | |
| 11 | |
| 12 | |
| 13 | |
| | |
| 14 | |
| 15 | |
| 16 17 | |
| 17 | |
| 18 | |
| 19 | |
| 20 | |
| 21 | |
| 22 | |
| 22 | |
| 23 | |
| 24 | |
| 25 | |
| 26 | |
| 27 | |
| 28 | |
| 29 | |
| 30 | |
| 31 | |
| | |
| 32 | |
| 33 | |
| 34 | |
| 35 | |
| 36 | |
| 37 | |
| 38 | |
| 39 | |
| 40 | |
| 40 41 | |
| | |
| 42 | |
| 43 | |
| 44 | |
| 45 | |
| 46 | |
| 47 | |
| 48 | |
| 49 | |
| 50 | |
| 51 | |
| 52 | |
| | |
| | |
| 54 | |
| 55 | |
| 56 | |
| 57 | |
| 58 | |
| 59 | |
| ~~~ | |

60

| 228 | |
|-----|---|
| 229 | After cleaning EHR data obtained from each site, there were 713 participants (out of |
| 230 | 1,201 participants randomized in PREPARE) included in these analyses. The remaining |
| 231 | patients in the PREPARE study (488) did not have their data included because the sites |
| 232 | did not provide EHR data. The breakdown of participants by site is in Table 1. Of these, |
| 233 | 350 (49.1%) were in the UCare Group and 363 (50.9%) were in the PARTICS Group. |
| 234 | Most participants were female and Non-Hispanic/Black (Table 2 for comparisons with |
| 235 | the full study cohort). As the University of Puerto Rico, a major H/L enrolling site, was |
| 236 | not able to provide EHR data, the cohort of participants included in this analysis has a |
| 237 | lower percent of H/L participants than the full study (p<0.001; Table 2). |

238

Table 1. Counts of Participants used in the EHR Data by Site (n = 713).

| | 1 |
|--------|-------|
| Site | Count |
| Site 1 | 14 |
| Site 2 | 21 |
| Site 3 | 58 |
| Site 4 | 34 |
| Site 5 | 57 |
| Site 6 | 79 |
| Site 7 | 86 |

| Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies. | MJ Open: first published as 10.1136/bmjopen-2024-088349 on 21 November 2024. Downloaded from http://bmjopen.bmj.com/ on June 13, 2025 at Agence Bibliogra |
|---|---|
|---|---|

| Site 9 48 Site 10 58 Site 11 42 Site 12 9 Site 13 71 Site 14 70 | |
|---|---|
| Site 11 42 Site 12 9 Site 13 71 | |
| Site 12 9 Site 13 71 | |
| Site 13 71 | |
| | |
| Site 14 70 | 1 |
| | 1 |
| Site 15 13 | |
| Site 16 37 | |

27 241

Table 2. Demographics and Comparisons with Main Study (n (%)).

| | PARTICS (n = 363) | UCare (n = 350) | Sig with Main Study |
|--------------------|-------------------|-----------------|---------------------|
| Overall (n = 713) | 363 (50.9%) | 350 (49.1%) | 0.722 |
| Female | 297 (81.8%) | 292 (83.4%) | 0.295 |
| Non-Hispanic/Black | 216 (59.5%) | 217 (62.0%) | <0.001 |

244 Changes in Asthma Controller Medication Prescriptions

As noted in Table 3, asthma controller medication prescription changes, without regard to the change direction, occurred over time (before and after enrollment; comparison of two time points) for both the UCare and PARTICS groups. Changes included addition or withdrawal of inhalers or medications, biologics, and leukotriene inhibitors, as well as

| ~ | abanges in decage of all modications. However, abanges were statistically similar, as |
|----|---|
| | changes in dosage of all medications. However, changes were statistically similar, so |
| b | both groups changed controller medications with similar frequency over the various tim |
| р | periods included in Table 3. |
| | |
| Т | Table 3. Changes in Asthma Medications Over Time (n (%)). |
| | PARTICS (n = |
| | Overall (n = 713) UCare (n = 350) 363) |
| | 12 Months Prior to Enrollment – Enrollment Month |
| | Changes Occurred 451 (63.3%) 219 (60.3%) 232 (66.3%) |
| | Enrollment Month – 15 Months After Enrollment |
| | Changes Occurred 491 (68.9%) 247 (68.0%) 244 (69.7%) |
| | Enrollment Month – 12 Months After Enrollment |
| | |
| | Changes Occurred 477 (66.9%) 239 (65.8%) 238 (68.0%) |
| | |
| N | Modelling of Electronic Health Record Data |
| | |
| A | After models with the individual demographic variables were completed (model include |
| ir | in supplemental materials for reference), each model contained the assigned step each |
| n | month as the dependent variable and the month, the group (PARTICS or UCare), the |
| s | site, the patients' decade of birth, and COVID-19 correction as independent variables. |
| | The patients' decade of birth and COVID-19 correction contributed significantly to the |
| Т | The patients decade of birth and OOVID TO concellent contributed significantly to the |
| | |
| ir | individual models which necessitates inclusion in the final model. After the final overall model (located in the Supplemental Materials), a spline was introduced to determine th |

differences between before and after Enrollment and to determine the effect of the

| 200 | | | | | | |
|-----|---|--------------------|------------------|----------------|--------|--|
| 266 | intervention using prescribers' written prescriptions. The next two models detail the LME | | | | | |
| 267 | with Spline accounting for before Enrollment (Table 4) and after Enrollment (Table 5). | | | | | |
| 268 | | | | | | |
| 269 | Model for Before Enro | llment (12 mont | hs prior throu | gh one month b | efore | |
| 270 | Enrollment; Table 4) | | | | | |
| 271 | | | | | | |
| 272 | Table 4. Final Before E | Enrollment LME | Results. | | | |
| | Parameter | Estimate | Standard | 95% CI | t | |
| | | | Error | | | |
| | | -2 Restricted Lo | g Likelihood: 24 | 1603.78 | | |
| | | Month: F(1, 568. | 00) = 198.82; p | < 0.001 | | |
| | | Group: F(1, 54 | 9.00) = 0.01; p | = 0.94 | | |
| | | Site: F(14, 549 | .00) = 8.47; p < | 0.001 | | |
| | De | ecade of Birth: F(| 4, 549.00) = 2.6 | 0; p = 0.04 | | |
| | Intercept (Baseline) | 2.80 | 0.30 | [2.20, 3.39] | 9.20* | |
| | Month | 0.15 | 0.01 | [0.13, 0.17] | 14.10* | |
| | UCare | 0.01 | 0.11 | [-0.20, 0.22] | 0.08 | |
| | PARTICS Reference | | | | | |
| | Site 1 | -0.10 | 0.46 | [-1.00, 0.81] | -0.21 | |
| | Site 2 | 1.12 | 0.38 | [0.38, 1.86] | 2.98* | |
| | Site 3 | 1.21 | 0.28 | [0.65, 1.76] | 4.29* | |
| | Site 4 | 0.62 | 0.32 | [-0.01, 1.25] | 1.93+ | |
| | | | | | | |

Page 17 of 31

| Site 5 | 1.50 | 0.28 | [0.95, 2.06] | 5.33* | |
|---------------------|-----------|------|----------------|--------|--|
| Site 6 | N/A | N/A | N/A | N/A | |
| Site 7 | 0.72 | 0.27 | [0.20, 1.24] | 2.72* | |
| Site 8 | 0.11 | 0.41 | [-0.70, 0.92] | 0.28 | |
| Site 9 | 0.43 | 0.29 | [-0.15, 1.01] | 1.46 | |
| Site 10 | -0.18 | 0.29 | [-0.75, 0.40] | -0.61 | |
| Site 11 | 0.10 | 0.31 | [-0.51, 0.72] | 0.33 | |
| Site 12 | -0.84 | 0.48 | [-1.80, 0.11] | -1.74+ | |
| Site 13 | 0.26 | 0.27 | [-0.28, 0.79] | 0.95 | |
| Site 14 | 0.25 | 0.28 | [-0.30, 0.79] | 0.89 | |
| Site 15 | -1.46 | 0.46 | [-2.36, -0.55] | -3.16* | |
| Site 16 | Reference | | | | |
| Born: 1940s & 1950s | 0.52 | 0.22 | [0.09, 0.94] | 2.38* | |
| Born: 1960s | 0.16 | 0.22 | [-0.27, 0.58] | 0.73 | |
| Born: 1970s | 0.10 | 0.22 | [-0.34, 0.54] | 0.43 | |
| Born: 1980s | 0.20 | 0.23 | [-0.26, 0.65] | 0.84 | |
| Born: 1990s & 2000s | | Refe | rence | | |

* p-value < 0.05

The UCare and PARTICS patients were at approximately the same step before
Enrollment. The months before Enrollment did show a significant decrease in controller
intensity over time (months were inputted as negative value). (Note: The data for before

| Group: $F(1, 631.01) = 4.72$; $p = 0.03$ Site: $F(15, 633.60) = 9.91$; $p < 0.001$ Decade of Birth: $F(4, 631.09) = 3.83$; $p = 0.004$ COVID Correction: $F(1, 9448.26) = 29.68$; $p < 0.001$ | | Enrollment took place e | ntirely before the | | | |
|--|-----|--|--|--|---|---|
| 279 assigned steps differed significantly between the sites. 280 Four sites (Sites 2, 3, 5, 7) had significantly higher steps of asthma controller 281 Four sites (Sites 2, 3, 5, 7) had significantly higher steps of asthma controller 282 medications compared with patients from Site 16 (reference site). One site (Site 15) had 283 significantly lower steps of asthma controller medications than patients from Site 16. 284 The assigned steps differed significantly with the patients' decade of birth. Patients bor 285 in the 1940s/1950s had significantly higher levels of asthma controller medications that 286 patients born in the 1990s/2000s (Table 4). 287 Model After Enrollment (one month after through the 15 months after Enrollment 289 Table 5. 290 Table 5. Final After Enrollment LME Results. 291 Table 5. Final After Enrollment LME Results. 292 -2 Restricted Log Likelihood: 33387.07 293 Month: F(1, 684.72) = 24.59; p < 0.001 | 70 | | | start of the CO | VID-19 pandemi | c.) The |
| 280 281 Four sites (Sites 2, 3, 5, 7) had significantly higher steps of asthma controller 282 medications compared with patients from Site 16 (reference site). One site (Site 15) had 283 significantly lower steps of asthma controller medications than patients from Site 16. 284 The assigned steps differed significantly with the patients' decade of birth. Patients bor 285 in the 1940s/1950s had significantly higher levels of asthma controller medications that 286 Model After Enrollment (one month after through the 15 months after Enrollment 287 Table 5. Final After Enrollment LME Results. 288 Parameter Estimate 290 Table 5. Final After Enrollment LME Results. 291 Table 5. Final After Enrollment LME Results. 292 Table 5. Final After Enrollment LME Results. 293 Table 5. Final After Enrollment LME Results. 294 Covertion: F(1, 681.72) = 24.59; p < 0.001 | .79 | assigned steps differed | significantly betw | veen the sites. | | |
| 282 redications compared with patients from Site 16 (reference site). One site (Site 15) has significantly lower steps of asthma controller medications than patients from Site 16. 283 significantly lower steps of asthma controller medications than patients from Site 16. 284 The assigned steps differed significantly with the patients' decade of birth. Patients bor 285 in the 1940s/1950s had significantly higher levels of asthma controller medications tha 286 patients born in the 1990s/2000s (Table 4). 287 288 288 Model After Enrollment (one month after through the 15 months after Enrollment 289 Table 5. Final After Enrollment LME Results. 290 291 291 Table 5. Final After Enrollment LME Results. 292 -2 Restricted Log Likelihood: 33387.07 293 -2 Restricted Log Likelihood: 33387.07 294 Month: F(1, 684.72) = 24.59; p < 0.001 | 80 | | | | | |
| 282 medications compared with patients from Site 16 (reference site). One site (Site 15) has significantly lower steps of asthma controller medications than patients from Site 16. 283 Significantly lower steps of asthma controller medications than patients from Site 16. 284 The assigned steps differed significantly with the patients' decade of birth. Patients bor 285 in the 1940s/1950s had significantly higher levels of asthma controller medications that 286 Model After Enrollment (one month after through the 15 months after Enrollment 287 Table 5. Final After Enrollment LME Results. 290 Table 5. Final After Enrollment LME Results. 291 Table 5. Final After Enrollment LME Results. 292 Context 293 Context 294 Context 295 Context 296 Context 297 Context 298 Context 299 Context 290 Context 291 Context 292 Context 293 Context 294 Context 295 Context 296 Context | 281 | Four sites (Sites 2, 3, 5, | 7) had significar | ntly higher steps | of asthma contr | oller |
| 283 significantly lower steps of asthma controller medications than patients from Site 16. 284 The assigned steps differed significantly with the patients' decade of birth. Patients bor 285 in the 1940s/1950s had significantly higher levels of asthma controller medications that 286 patients born in the 1990s/2000s (Table 4). 287 Model After Enrollment (one month after through the 15 months after Enrollment 288 Table 5) 290 Table 5. Final After Enrollment LME Results. Parameter Estimate Standard 95% Cl t -2 Restricted Log Likelihood: 33387.07 Month: F(1, 684.72) = 24.59; p < 0.001 | 282 | medications compared | with patients from | n Site 16 (refere | nce site). One si | te (Site 15) had |
| 285 in the 1940s/1950s had significantly higher levels of asthma controller medications that 286 patients born in the 1990s/2000s (Table 4). 287 Model After Enrollment (one month after through the 15 months after Enrollment 288 Model After Enrollment (one month after through the 15 months after Enrollment 289 Table 5) 290 291 291 Table 5. Final After Enrollment LME Results. Parameter Estimate 28 Error -2 Restricted Log Likelihood: 33387.07 Month: F(1, 684.72) = 24.59; p < 0.001 | 283 | significantly lower steps | of asthma contro | oller medications | s than patients fr | om Site 16. |
| patients born in the 1990s/2000s (Table 4). Model After Enrollment (one month after through the 15 months after Enrollment Table 5) Table 5. Final After Enrollment LME Results. Parameter Estimate Standard 95% Cl t Fror -2 Restricted Log Likelihood: 33387.07 Month: F(1, 684.72) = 24.59; p < 0.001 Group: F(1, 631.01) = 4.72; p = 0.03 Site: F(15, 633.60) = 9.91; p < 0.001 Decade of Birth: F(4, 631.09) = 3.83; p = 0.004 COVID Correction: F(1, 9448.26) = 29.68; p < 0.001 | 284 | The assigned steps diffe | ered significantly | with the patients | s' decade of birth | n. Patients born |
| 287288Model After Enrollment (one month after through the 15 months after Enrollment289Table 5)290291291Table 5. Final After Enrollment LME Results.ParameterEstimateStandard95% Cl95t-2 Restricted Log Likelihood: 33387.07Month: $F(1, 684.72) = 24.59; p < 0.001$ Group: $F(1, 631.01) = 4.72; p = 0.03$ Site: $F(15, 633.60) = 9.91; p < 0.001$ Decade of Birth: $F(4, 631.09) = 3.83; p = 0.004$ COVID Correction: $F(1, 9448.26) = 29.68; p < 0.001$ | 285 | in the 1940s/1950s had | significantly high | er levels of asth | ima controller m | edications than |
| 287288Model After Enrollment (one month after through the 15 months after Enrollment289Table 5)290291291Table 5. Final After Enrollment LME Results.ParameterEstimateStandard95% Cl95%t-2 Restricted Log Likelihood: 33387.07Month: $F(1, 684.72) = 24.59; p < 0.001$ Group: $F(1, 631.01) = 4.72; p = 0.03$ Site: $F(15, 633.60) = 9.91; p < 0.001$ Decade of Birth: $F(4, 631.09) = 3.83; p = 0.004$ COVID Correction: $F(1, 9448.26) = 29.68; p < 0.001$ | 286 | patients born in the 199 | 0s/2000s (Table | 4). | | |
| Model After Enrollment (one month after through the 15 months after Enrollment289Table 5)290291291Table 5. Final After Enrollment LME Results.ParameterEstimateStandard95% Cl-2 Restricted Log Likelihood: 33387.07Month: $F(1, 684.72) = 24.59; p < 0.001$ Group: $F(1, 631.01) = 4.72; p = 0.03$ Site: $F(15, 633.60) = 9.91; p < 0.001$ Decade of Birth: $F(4, 631.09) = 3.83; p = 0.004$ COVID Correction: $F(1, 9448.26) = 29.68; p < 0.001$ | | | Ċ, | , | | |
| Z89 Table 5) 290 291 Table 5. Final After Enrollment LME Results. Parameter Estimate Standard 95% CI t -2 Restricted Log Likelihood: 33387.07 Month: $F(1, 684.72) = 24.59; p < 0.001$ Group: $F(1, 631.01) = 4.72; p = 0.03$ Site: $F(15, 633.60) = 9.91; p < 0.001$ Decade of Birth: $F(4, 631.09) = 3.83; p = 0.004$ COVID Correction: $F(1, 9448.26) = 29.68; p < 0.001$ | | Model After Enrollmen | it (one month af | ter through the | 15 months after | er Enrollment: |
| 290 Table 5. Final After Enrollment LME Results. Parameter Estimate Standard 95% CI t -2 Restricted Log Likelihood: 33387.07 -2 Restricted Log Likelihood: 33387.07 Month: $F(1, 684.72) = 24.59; p < 0.001$ Group: $F(1, 631.01) = 4.72; p = 0.03$ Site: $F(15, 633.60) = 9.91; p < 0.001$ Decade of Birth: $F(4, 631.09) = 3.83; p = 0.004$ COVID Correction: $F(1, 9448.26) = 29.68; p < 0.001$ | | | | | | , |
| Table 5. Final After Enrollment LME Results. Parameter Estimate Standard 95% CI t -2 Restricted Log Likelihood: 3387.07 Month: $F(1, 684.72) = 24.59; p < 0.001$ Group: $F(1, 631.01) = 4.72; p = 0.03$ Site: $F(15, 633.60) = 9.91; p < 0.001$ Decade of Birth: $F(4, 631.09) = 3.83; p = 0.004$ COVID Correction: $F(1, 9448.26) = 29.68; p < 0.001$ | | | | | | |
| Parameter Estimate Standard 95% CI t $Error$ $Error$ -2 Restricted Log Likelihood: 33387.07 Month: F(1, 684.72) = 24.59; p < 0.001 | | Table 5. Final After Fr | | | | |
| Parameter Estimate Standard 95% CI t Error -2 Restricted Log Likelihood: 33387.07 -2 Restricted Log Likelihood: 33387.07 Month: F(1, 684.72) = 24.59; p < 0.001 | 91 | Table 5. Final After En | roliment LWE R | esults. | | |
| -2 Restricted Log Likelihood: 33387.07 Month: F(1, 684.72) = 24.59 ; p < 0.001 Group: F(1, 631.01) = 4.72 ; p = 0.03 Site: F(15, 633.60) = 9.91 ; p < 0.001 Decade of Birth: F(4, 631.09) = 3.83 ; p = 0.004 COVID Correction: F(1, 9448.26) = 29.68 ; p < 0.001 | | Parameter | Estimate | Standard | 95% CI | t |
| Month: $F(1, 684.72) = 24.59$; $p < 0.001$ Group: $F(1, 631.01) = 4.72$; $p = 0.03$ Site: $F(15, 633.60) = 9.91$; $p < 0.001$ Decade of Birth: $F(4, 631.09) = 3.83$; $p = 0.004$ COVID Correction: $F(1, 9448.26) = 29.68$; $p < 0.001$ | | | | Error | 0 | |
| Group: $F(1, 631.01) = 4.72$; $p = 0.03$ Site: $F(15, 633.60) = 9.91$; $p < 0.001$ Decade of Birth: $F(4, 631.09) = 3.83$; $p = 0.004$ COVID Correction: $F(1, 9448.26) = 29.68$; $p < 0.001$ | | | -2 Restricted Lo | g Likelihood: 33 | 3387.07 | |
| Site: F(15, 633.60) = 9.91; p < 0.001 Decade of Birth: F(4, 631.09) = 3.83; p = 0.004 COVID Correction: F(1, 9448.26) = 29.68; p < 0.001 | | | Month: F(1, 684 | 72) = 24.59; p · | < 0.001 | |
| Site: F(15, 633.60) = 9.91; p < 0.001 Decade of Birth: F(4, 631.09) = 3.83; p = 0.004 COVID Correction: F(1, 9448.26) = 29.68; p < 0.001 | 44 | | | | | |
| Decade of Birth: F(4, 631.09) = 3.83; p = 0.004 COVID Correction: F(1, 9448.26) = 29.68; p < 0.001 | | | 8.60) = 9.91; p < | 0.001 | | |
| COVID Correction: F(1, 9448.26) = 29.68; p < 0.001 | | Decade of Birth: F(4, 631.09) = 3.83; p = 0.004 | | | | |
| Intercent (Baseline) 2.04 0.29 [1.48.2.60] 7.16* | | | D Correction: F(1 | l, 9448.26) = 29 | .68; p < 0.001 | |
| | | COVI | | | | |
| 50 51 52 53 54 | | 81 82 83 84 85 86 87 88 88 89 90 | Four sites (Sites 2, 3, 5, medications compared visions is significantly lower steps difference in the 1940s/1950s had patients born in the 199 Model After Enrollment Table 5) Table 5. Final After Enrol | Four sites (Sites 2, 3, 5, 7) had significant medications compared with patients from significantly lower steps of asthma control The assigned steps differed significantly in the 1940s/1950s had significantly high patients born in the 1990s/2000s (Table patients born in the 1990s/2000s (Table Model After Enrollment (one month af Table 5) Table 5. Final After Enrollment LME R Parameter Estimate -2 Restricted Low Month: F(1, 684 Group: F(1, 63) Site: F(15, 633) | 81Four sites (Sites 2, 3, 5, 7) had significantly higher steps82medications compared with patients from Site 16 (refere83significantly lower steps of asthma controller medications84The assigned steps differed significantly with the patient85in the 1940s/1950s had significantly higher levels of asth86patients born in the 1990s/2000s (Table 4).87Model After Enrollment (one month after through the89Table 5)909191Table 5. Final After Enrollment LME Results.92Parameter93Estimate94Standard94Enror95-2 Restricted Log Likelihood: 3396Month: F(1, 684.72) = 24.59; p97Group: F(1, 631.01) = 4.72; p98Site: F(15, 633.60) = 9.91; p | Four sites (Sites 2, 3, 5, 7) had significantly higher steps of asthma contr medications compared with patients from Site 16 (reference site). One si significantly lower steps of asthma controller medications than patients fr The assigned steps differed significantly with the patients' decade of birth in the 1940s/1950s had significantly higher levels of asthma controller me patients born in the 1990s/2000s (Table 4). Model After Enrollment (one month after through the 15 months after Table 5) Table 5. Final After Enrollment LME Results. Parameter Estimate Standard 95% CI Error -2 Restricted Log Likelihood: 33387.07 Month: F(1, 684.72) = 24.59; p < 0.001 Group: F(1, 631.01) = 4.72; p = 0.03 Site: F(15, 633.60) = 9.91; p < 0.001 |

Page 19 of 31

BMJ Open

| Month | -0.05 | 0.01 | [-0.06, -0.03] | -4.95* | |
|---------------------|-------|-----------|----------------|--------|--|
| | | | | | |
| UCare | 0.20 | 0.09 | [0.02, 0.39] | 2.17* | |
| PARTICS | | Ref | erence | | |
| Site 1 | -0.37 | 0.39 | [-1.13, 0.40] | -0.94 | |
| Site 2 | 1.40 | 0.33 | [0.75, 2.05] | 4.20* | |
| Site 3 | 1.57 | 0.26 | [1.05, 2.09] | 5.97* | |
| Site 4 | 1.31 | 0.29 | [0.74, 1.89] | 4.49* | |
| Site 5 | 0.96 | 0.26 | [0.44, 1.48] | 3.63* | |
| Site 6 | -0.03 | 0.25 | [-0.52, 0.45] | -0.14 | |
| Site 7 | 0.57 | 0.25 | [0.08, 1.06] | 2.30* | |
| Site 8 | 0.43 | 0.39 | [-0.34, 1.20] | 1.09 | |
| Site 9 | 0.41 | 0.28 | [-0.13, 0.95] | 1.49 | |
| Site 10 | 0.43 | 0.26 | [-0.08, 0.94] | 1.65+ | |
| Site 11 | 0.59 | 0.29 | [0.02, 1.15] | 2.05* | |
| Site 12 | 0.31 | 0.47 | [-0.62, 1.23] | 0.65 | |
| Site 13 | -0.17 | 0.27 | [-0.69, 0.35] | -0.64 | |
| Site 14 | 0.56 | 0.26 | [0.05, 1.08] | 2.17* | |
| Site 15 | -1.36 | 0.45 | [-2.24, -0.48] | -3.03* | |
| Site 16 | | Reference | | | |
| Born: 1940s & 1950s | 0.46 | 0.19 | [0.10, 0.83] | 2.49* | |
| Born: 1960s | 0.00 | 0.18 | [-0.36, 0.36] | 0.01 | |
| Born: 1970s | 0.24 | 0.19 | [-0.13, 0.62] | 1.27 | |
| Born: 1980s | 0.30 | 0.20 | [-0.09, 0.69] | 1.49 | |

| 2 3 | |
|----------------------------------|----|
| 4 5 6 7 | |
| 7 8 | |
| 9 10 | |
| 11 | 29 |
| 12 13 | 29 |
| 14 15 16 | 29 |
| 10 17 18 | 29 |
| 19 20 | 29 |
| 21 22 22 | 29 |
| 21 22 23 24 25 26 | 29 |
| 27 | 29 |
| 28 29 | 30 |
| 30 31 32 | 30 |
| 33 34 | 30 |
| 35 36 | 30 |
| 37 38 | 30 |
| 39 40 41 | 30 |
| 42 43 | 30 |
| 44 45 | 30 |
| 46 47 48 | 30 |
| 48 49 50 | 30 |
| 51 52 | 31 |
| 53 54 | 31 |
| 55 56 | |
| 57 58 | |
| 59 | |
| 60 | |

| | Born: 1990s & 2000s | | Refe | erence | |
|---|---|-------------------|--------------------|---------------------|-------------------|
| | No COVID-19 | 0.38 | 0.07 | [0.24, 0.51] | 5.45* |
| | COVID-19 Present Reference | | | | |
| 2 | * p-value < 0.05 | | | | |
| 3 | | | | | |
| 1 | The UCare patients were | e at a significan | tly higher asthm | na controller medi | cation step |
| 5 | overall than the PARTIC | S patients acro | ss all time perio | ds for the time af | er Enrollment. |
| 5 | However, the months aft | er Enrollment c | lid show a signit | ficant decrease in | controller |
| 7 | intensity over time for bo | th groups, whic | h could be due | to the COVID-19 | pandemic. |
| 3 | When compared to the N | lodel Before E | nrollment, the di | fference between | the UCare and |
| 9 | PARTICS patients with the | ne changes ove | er time indicate | that the PARTICS | patients had |
|) | significantly greater decr | ease in the inte | ensity of their co | ntroller therapy co | ompared to |
| 1 | UCare patients (Tables 4 | and 5). | | | |
| 2 | | | | | |
| 3 | The assigned steps diffe | red significantly | y between the s | ites. Seven sites (| Sites 2, 3, 4, 5, |
| 1 | 7, 11, 14) had significantly higher steps of asthma controller medications than patients | | | | |
| 5 | from Site 16 (reference site). One site (Site 15) had significantly lower steps of asthma | | | | |
| 5 | controller medications than patients from Site 16. The assigned steps differed | | | | |
| 7 | significantly with the patients' decade of birth. Patients born in the 1940s/1950s had | | | | |
| 3 | significantly higher levels of asthma controller medications than patients born in the | | | | |
| Э | 1990s/2000s. Lastly, in the months when COVID-19 was not present (before April | | | | |
| D | 2020), both groups of pa | tients had a sig | nificantly highe | r asthma controlle | er medication |
| - | level than after the COVI | D-19 pandemic | c began (Table 🤅 | 5). | |
| | | | | | |

60

| 1 2 | | |
|--|-----|--|
| 2 3 4 | 312 | |
| 5 6 | 313 | DISCUSSION |
| 7 8 9 10 11 12 13 | 314 | This study shows, through prescribers' written prescriptions, there was a greater |
| | 315 | decrease in asthma controller medication level over time (after Enrollment) in the |
| | 316 | PARTICS patients compared with the UCare patients with both groups starting at the |
| 14 15 | 317 | same asthma controller medication level. The decrease in intensity reduces, to some |
| 16 17 18 | 318 | degree, the expected increase in total ICS exposure that would result from adopting the |
| 19 20 | 319 | PARTICS strategy. The results in this sub-study complement and confirm the results in |
| 21 22 | 320 | the main effects paper that that shows that self-reported ICS-containing controller refills |
| 23 24 25 | 321 | were lower for participants assigned to PARTICS vs usual care. ³⁰ Between this sub- |
| 23 26 27 28 29 30 31 32 | 322 | study and the main effects paper, the participants' reported and prescribers' EHR data |
| | 323 | indicate decreased asthma controller medication use over time for the PARTICS |
| | 324 | patients compared with the UCare patients, even with correcting for COVID-19. When |
| 33 34 | 325 | combined with the patient self-reported levels of controller ICS use and rescue ICS |
| 35 36 | 326 | fulfillment data from the main effects paper, this sub-study supports that PARTICS |
| 37 38 39 | 327 | improves outcomes at the population level, as the intensity of ICS controller therapy |
| 40 41 | 328 | dropped as well as self-reported controller ICS use. Treating clinicians were free to |
| 42 43 | 329 | adjust asthma medications as deemed necessary during the study. Primary asthma |
| 44 45 | 330 | treating clinicians were not provided the monthly Asthma Control Test scores that were |
| 46 47 48 | 331 | collected for research purposes, but patients may have been more aware of their |
| 49 50 | 332 | asthma symptoms through repeated completion of this instrument. For many patients |
| 51 52 | 333 | the primary asthma treating clinician was not the research prescribing clinician, but the |
| 53 54 55 | 334 | treating clinician would have been aware of the study medication. While it is not |
| 56 57 | | |

Protected by copyright, including for uses related to text

and

possible to determine if the drop in controller ICS dose, at the population level, was in response to the added as needed ICS, the increase in controller ICS dosage for the control patients would suggest changes were more likely to be based on asthma control and not perceived total steroid burden.

While the results of this sub-study confirm the results of the main effects paper, there are limitations. EHR data have inherent missingness and can have gaps due to infrequent visits and prescribing activities. In particular, assumptions concerning the length of time a prescription was active were made to determine an active medical regimen. While this may have affected the exact level for a given individual, the assumptions were evenly applied across both groups. Further, some individuals were on dual ICS inhalers not counting the study-prescribed beclomethasone, and these individuals were assigned based on the highest potency of any of the non-study prescribed ICS inhalers. Again, while this may have affected the ICS level of an individual, the approach was evenly applied at all times across both groups. Thus, neither of these processes would bias the results for either of the study arms. In addition, not every site within PREPARE provided data, but we had data from the majority of sites. This reduction in ICS controller intensity in the PARTICS group was accompanied with a significant reduction in annualized exacerbation rates in this group,³⁰ though total ICS use considering both controller and rescue use likely increased to some degree.

BMJ Open: first published as 10.1136/bmjopen-2024-088349 on 21 November 2024. Downloaded from http://bmjopen.bmj.com/ on June 13, 2025 at Agence Bibliographique de Enseignement Superieur (ABES) . ur (ABES) . data mining, Al training, and similar technologies

Page 23 of 31

BMJ Open

The results show that there were significant changes over time (after Enrollment) as well as significant differences between the PARTICS and UCare groups, participating sites, participants' decades of birth, and the COVID-19 correction. In the spline regressions, the UCare and PARTICS patients were comparable before enrollment, and differences occurred after enrollment in PREPARE. This effect is consonant with our reported reduction in exacerbations in the PREPARE cohort during the COVID pandemic.³⁶ The significant effect due to COVID-19 could be due to a variety of factors including changes in lifestyles that occurred such as working from home and a reduction in air pollution due to fewer cars on the road.³⁶ This effect could be further studied using air pollution data around the patents' dwellings. Select sites provided their patients with significantly higher (or lower) asthma controller medications than the reference site (Site 16). The differences could be accounted for by different overall participant asthma severity across sites,³¹ clinicians' prescribing patterns, organizational policies, or environmental factors. Though all clinicians providing asthma care for PREPARE participants completed the Asthma IQ program³⁷ to help standardize care, this intervention would not affect baseline (or pre-baseline) prescribing patterns, which were in place prior to the training. Further exploration into the reasons for the differences is warranted. This sub-study shows that clinicians' prescribing patterns did change over time, and the PARTICS patients were prescribed lower doses of asthma controller medications by the end of the study.

| 2 3 4 | 380 | |
|--|-----|---|
| 5 6 7 | 381 | Acknowledgements: We would like to acknowledge all study participants for their time |
| 8 9 | 382 | and dedication. We would also like to acknowledge the PREPARE Operations Team |
| 10 11 12 | 383 | and Nancy Maher. We would also like to acknowledge the PREPARE site principal |
| 13 14 | 384 | investigators. |
| 15 16 17 | 385 | |
| 17 18 19 | 386 | Availability of Data: Data available upon reasonable request to the corresponding |
| 20 21 | 387 | author. |
| 22 23 24 | 388 | |
| 25 26 | 389 | Patient and Public Involvement: Patients and the public were not involved in the |
| 20 27 28 | 390 | design, conduct, reporting, and dissemination of this secondary data analysis. |
| 29 30 | 391 | |
| 31 32 33 | 392 | Financial Support: Supported by a PCORI Award (PCS-1504-30283, to Dr. Israel), the |
| 34 35 | 393 | Gloria M. and Anthony C. Simboli Distinguished Chair in Asthma Research award (to |
| 36 37 | 394 | Dr. Israel), and by grants from the National Institute of Allergy and Infectious Diseases |
| 38 39 40 | 395 | (K23AI125785, to Dr. Cardet) and the American Lung Association–American Academy |
| 40 41 42 | 396 | of Allergy, Asthma, and Immunology (AI-835475, to Dr. Cardet). QVAR and QVAR |
| 43 44 | 397 | RediHaler inhalers were provided free of charge and funding for the AssistRx pharmacy |
| 45 46 47 | 398 | was provided by Teva Pharmaceuticals. NIOX VERO devices for measuring exhaled |
| 47 48 49 | 399 | nitric oxide were provided free of charge by Circassia Pharmaceuticals. |
| 50 51 | 400 | |
| 52 53 54 55 56 57 57 | 401 | Conflicts of Interest: |
| 58 59 60 | | 23 For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml |

Page 25 of 31

57 58 59

60

BMJ Open

| 1 2 | | |
|----------------|-----|--|
| 2 3 4 | 402 | Elisabeth Callen: Dr. Callen receives support for other work (paid directly to her |
| 5 6 | 403 | institution) from Otsuka Pharmaceuticals, NIH, PCORI, HRSA, United Health |
| 7 8 | 404 | Foundation, SAMHSA, Merck, Eli Lilly, CDC, and Takeda. |
| 9 10 11 | 405 | Elliot Israel: Dr. Israel receives support for other work (paid directly to his institution) |
| 12 13 | 406 | from AstraZeneca, Avillion Mandala/Denali, Circassia, Gossamer Bio, NIH, Novartis, |
| 14 15 | 407 | and PCORI; he receives consulting fees from Allergy and Asthma Network, Amgen, |
| 16 17 18 | 408 | AstraZeneca, Avillion, GlaxoSmithKline, Merck, NHLBI, Novartis, Pneuma Respiratory, |
| 19 20 | 409 | Regeneron, Sanofi Genzyme, TEVA, and Cowen; he receives royalties from UpToDate |
| 21 22 | 410 | - Wolters Kluwer; he has been paid honoraria from TEVA, Cowen, and Westchester |
| 23 24 | 411 | Medical Center; he has been paid for expert testimony by Cambridge Medical Experts, |
| 25 26 27 | 412 | Danaher Lagnese, and SettlePou; he has been paid for Participation on a Data Safety |
| 28 29 | 413 | Monitoring Board or Advisory Board by Novartis; he is a member of the coordinating |
| 30 31 | 414 | committed for National Asthma Education Prevention Program and he is on the editorial |
| 32 33 34 | 415 | board for the Journal of Allery and Clinical Immunology and the Journal of Allergy & |
| 35 36 | 416 | Clinical Immunology, in Practice; he owns stock in Nesos Corp; and he has received a |
| 37 38 | 417 | study drug for an unrelated study from Genentech, Sun Pharmaceuticals, Laurel |
| 39 40 | 418 | Pharmaceuticals, Om Pharmaceuticals, Nestle, CSL Behring, Glaxo, and Sanofi |
| 41 42 43 | 419 | Regeneron. |
| 44 45 | 420 | Juan Carlos Cardet: Dr Cardet reports receiving honoraria from AstraZeneca, Chiesi, |
| 46 47 | 421 | GSK, Genentech, and Sanofi for work on advisory boards and delivering lectures on |
| 48 49 | 422 | asthma pathobiology and management. |
| 50 51 52 | | |
| 53 54 | | |
| 55 56 | | |

Page 26 of 31 BMJ Open: first published as 10.1136/bmjopen-2024-088349 on 21 November 2024. Downloaded from http://bmjopen.bmj.com/ on June 13, 2025 at Agence Bibliographique de Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text data mining, AI training, and similar technologies

and

Anne Fuhlbrigge: Dr Fuhlbrigge an unpaid consultant to Teva, AstraZeneca and Novartis pharmaceuticals for epidemiologic analyses related to asthma outcomes and a co-investigator for the PREPARE, funded through PCORI. Gabriela Gaona: declares no conflict of interest. **Wilson Pace:** Dr. Pace's organization has received funding via subcontracts from CDC, PCORI, NIH, Boehringer Ingelheim, ONC, Tabula Rasa Healthcare, and Astra-Zeneca; his organization received consulting fees for his work from Boehringer Ingelheim; his organization has received payment for expert testimony; he is on the Advisory Board (paid) for AT Still Research Foundation and an Advisory board and Executive Committee member (unpaid) for COPD Foundation 360 Network; he owns stock through trust in Johnson and Johnson, Eli Lilly, Novo-Nordisk, Pfizer, Novartis, Moderna, and Amgen; he received grant and writing support for an unrelated project from Boehringer Ingelheim; and is an unpaid members of Colorado Medicaid Provider Rate Review Committee. Brian Manning: declares no conflict of interest. Elizabeth Staton: declares no conflict of interest.

| 1 ว | | |
|----------|-----|---|
| 2 3 | | |
| 4 | 440 | References |
| 5 | 441 | |
| 6 | 442 | 1. Centers for Disease Control and Prevention. Asthma in the US 2011 [updated May 3, 2011. Available |
| 7 | 443 | from: https://www.cdc.gov/vitalsigns/asthma/index.html accessed October 2 2021. |
| 8 | 444 | 2. Zahran HS, Bailey CM, Damon SA, et al. Vital Signs: Asthma in Children - United States, 2001-2016. |
| 9 | 445 | MMWR Morb Mortal Wkly Rep 2018;67(5):149-55. doi: 10.15585/mmwr.mm6705e1 [published |
| 10 | 446 | Online First: 2018/02/09] |
| 11 12 | 447 | 3. Healthy Schools Campaign. Five Health-Related Causes of Chronic Absenteeism 2016 [updated August |
| 12 13 | 448 | 29, 2016. Available from: https://healthyschoolscampaign.org/blog/five-health-related-causes- |
| 14 | 449 | of-chronic-absenteeism/ accessed October 2 2021. |
| 15 | 450 | 4. McGregor MC, Krings JG, Nair P, Castro M. Role of Biologics in Asthma. Am J Respir Crit Care Med |
| 16 | 451 | 2019;199(4):433-45. doi: 10.1164/rccm.201810-1944CI [published Online First: 2018/12/12] |
| 17 | 452 | 5. Institute for Clinical and Economic Review. Biologic Therapies for Treatment of Asthma Associated |
| 18 | 453 | with Type 2 Inflammation: Effectiveness, Value, and Value-Based Price Benchmarks. Final |
| 19 | 454 | Evidence Report 2018 [updated December 20, 2018. Available from: |
| 20 | 455 | https://icer.org/assessment/asthma-2018/ accessed October 2 2021. |
| 21 22 | 456 | 6. Peters M. Single-inhaler combination therapy for maintenance and relief of asthma: a new strategy in |
| 22 | 457 | disease management. <i>Drugs</i> 2009;69(2):137-50. doi: 10.2165/00003495-200969020-00001 |
| 23 24 | 458 | [published Online First: 2009/02/21] |
| 25 | 459 | 7. O'Byrne PM, Bisgaard H, Godard PP, et al. Budesonide/formoterol combination therapy as both |
| 26 | 460 | maintenance and reliever medication in asthma. Am J Respir Crit Care Med 2005;171(2):129-36. |
| 27 | 461 | doi: 10.1164/rccm.200407-884OC [published Online First: 2004/10/27] |
| 28 | 462 | 8. Rabe KF, Pizzichini E, Stallberg B, et al. Budesonide/formoterol in a single inhaler for maintenance and |
| 29 | 463 | relief in mild-to-moderate asthma: a randomized, double-blind trial. Chest 2006;129(2):246-56. |
| 30 | 464 | doi: 10.1378/chest.129.2.246 [published Online First: 2006/02/16] |
| 31 | 465 | 9. Scicchitano R, Aalbers R, Ukena D, et al. Efficacy and safety of budesonide/formoterol single inhaler |
| 32 33 | 466 | therapy versus a higher dose of budesonide in moderate to severe asthma. Curr Med Res Opin |
| 34 | 467 | 2004;20(9):1403-18. doi: 10.1185/030079904X2051 [published Online First: 2004/09/24] |
| 35 | 468 | 10. Jenkins CR, Eriksson G, Bateman ED, et al. Efficacy of budesonide/formoterol maintenance and |
| 36 | 469 | reliever therapy compared with higher-dose budesonide as step-up from low-dose inhaled |
| 37 | 470 | corticosteroid treatment. BMC Pulm Med 2017;17(1):65. doi: 10.1186/s12890-017-0401-y |
| 38 | 471 | [published Online First: 2017/04/22] |
| 39 | 472 | 11. Bisgaard H, Le Roux P, Bjamer D, et al. Budesonide/formoterol maintenance plus reliever therapy: a |
| 40 | 473 | new strategy in pediatric asthma. <i>Chest</i> 2006;130(6):1733-43. doi: 10.1378/chest.130.6.1733 |
| 41 42 | 474 | [published Online First: 2006/12/15] |
| 42 43 | 475 | 12. Global Initiative for Asthma. Global strategy for asthma management and prevention 2021 report. |
| 44 | 476 | 2020 [Available from: https://ginasthma.org/gina-reports/ accessed October 2 2021. |
| 45 | 477 | 13. Global Initiative for Asthma. Difficult-to-treat and severe asthma in adolescent and adult patients. |
| 46 | 478 | Diagnosis and management 2019 [Available from: https://ginasthma.org/gina-reports/gina- |
| 47 | 479 | 2020-full-reportfinalwms accessed October 2 2021. |
| 48 | 480 | 14. National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working |
| 49 | 481 | Group. 2020 Focused Update to the Asthma Management Guidelines Summary from: A Report |
| 50 51 | 482 | from the National Asthma Education and Prevention Program Coordinating Committee Expert |
| 51 52 | 483 | Panel Working Group 2020 [Available from: https://www.nhlbi.nih.gov/health-topics/all- |
| 53 | 484 | publications-and-resources/2020-focused-updates-asthma-management-guidelines accessed |
| 54 | 485 | October 1 2021. |
| 55 | | |
| 56 | | |
| 57 | | |
| 58 | | |
| 59 60 | | 26 For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml |
| 00 | | · · · · · · · · · · · · · · · · · · · |

| 2 | | |
|----------|------------|---|
| 3 | 486 | 15. Centers for Disease Control and Prevention. Asthma Attacks in the Past 12 Months by Year 2019 |
| 4 | 487 | [Available from: https://www.cdc.gov/asthma/data-visualizations/health- |
| 5 | 488 | outcomes.htm#anchor_1569609411376 accessed October 2 2021. |
| 6 | 489 | 16. Centers for Disease Control and Prevention. Asthma Attacks among People with Current Asthma, |
| 7 | 490 | 2014–2017 2019 [Available from: <u>https://www.cdc.gov/asthma/asthma_stats/attacks-current-</u> |
| 8 | 491 | asthma.htm accessed October 2 2021. |
| 9 10 | 491 | 17. Moorman JE, Akinbami LJ, Bailey CM, et al. National surveillance of asthma: United States, 2001- |
| 10 | | |
| 12 | 493 | 2010. Vital Health Stat 3 2012(35):1-58. [published Online First: 2013/11/21] |
| 13 | 494 | 18. Cardet JC, Chang KL, Rooks BJ, et al. Socioeconomic status associates with worse asthma morbidity |
| 14 | 495 | among Black and Latinx adults. J Allergy Clin Immunol 2022 doi: 10.1016/j.jaci.2022.04.030 |
| 15 | 496 | [published Online First: 2022/05/22] |
| 16 | 497 | 19. Cardet JC, Shenoy K, Baydur A, et al. Caribbean Latinx with Moderate-Severe Asthma Bear Greater |
| 17 | 498 | Asthma Morbidity than Othe Latinx. Journal of Allergy and Clinical Immunology |
| 18 | 499 | 2022;150(5):1106 <mark>-</mark> 13. doi: 10.1016/j.jaci.2022.05.026 |
| 19 | 500 | 20. Szentpetery SE, Forno E, Canino G, Celedón JC. Asthma in Puerto Ricans: Lessons from a high-risk |
| 20 | 501 | population. J Allergy Clin Immunol 2016;138(6):1556-58. doi: 10.1016/j.jaci.2016.08.047 |
| 21 | 502 | [published Online First: 2016/10/19] |
| 22 | 503 | 21. Bartolomei-Díaz JA, Amill-Rosario A, Claudio L, Hernández W. Asthma mortality in Puerto Rico: 1980- |
| 23 | 504 | 2007. J Asthma 2011;48(2):202-9. doi: 10.3109/02770903.2010.528498 [published Online First: |
| 24 | 505 | 2010/11/03] |
| 25 | 506 | 22. British Thorasic Society. BTS/SIGN British Guideline on the Management of Asthma 2021 [updated |
| 26 | 507 | 12/2021. Available from: https://www.brit-thoracic.org.uk/quality- |
| 27 28 | 508 | improvement/guidelines/asthma/ accessed 1/7 2022. |
| 28 29 | 508 | 23. Boushey HA, Sorkness CA, King TS, et al. Daily versus as-needed corticosteroids for mild persistent |
| 30 | 510 | |
| 31 | | asthma. <i>N Engl J Med</i> 2005;352(15):1519-28. doi: 10.1056/NEJMoa042552 [published Online |
| 32 | 511 | First: 2005/04/15] |
| 33 | 512 | 24. Papi A, Canonica GW, Maestrelli P, et al. Rescue use of beclomethasone and albuterol in a single |
| 34 | 513 | inhaler for mild asthma. <i>N Engl J Med</i> 2007;356(20):2040-52. doi: 10.1056/NEJMoa063861 |
| 35 | 514 | [published Online First: 2007/05/18] |
| 36 | 515 | 25. Calhoun WJ, Ameredes BT, King TS, et al. Comparison of physician-, biomarker-, and symptom-based |
| 37 | 516 | strategies for adjustment of inhaled corticosteroid therapy in adults with asthma: the BASALT |
| 38 | 517 | randomized controlled trial. JAMA 2012;308(10):987-97. doi: 10.1001/2012.jama.10893 |
| 39 | 518 | [published Online First: 2012/09/13] |
| 40 | 519 | 26. Rabe KF, Atienza T, Magyar P, et al. Effect of budesonide in combination with formoterol for reliever |
| 41 | 520 | therapy in asthma exacerbations: a randomised controlled, double-blind study. Lancet |
| 42 | 521 | 2006;368(9537):744-53. doi: 10.1016/S0140-6736(06)69284-2 [published Online First: |
| 43 44 | 522 | 2006/08/29] |
| 44 45 | 523 | 27. Miller NH. Compliance with treatment regimens in chronic asymptomatic diseases. The American |
| 46 | 524 | Journal of Medicine 1997;102(2A):43-49. |
| 47 | 525 | 28. Haynes RB, Ackloo E, Sahota N, et al. Interventions for enhancing medication adherence. <i>Cochrane</i> |
| 48 | 526 | Database Syst Rev 2008(2):CD000011. doi: 10.1002/14651858.CD000011.pub3 [published |
| 49 | 527 | Online First: 2008/04/22] |
| 50 | 528 | 29. Papi A, Corradi M, Pigeon-Francisco C, et al. Beclometasone-formoterol as maintenance and reliever |
| 51 | | |
| 52 | 529 530 | treatment in patients with asthma: a double-blind, randomised controlled trial. <i>Lancet Respir</i> |
| 53 | | Med 2013;1(1):23-31. doi: 10.1016/S2213-2600(13)70012-2 [published Online First: |
| 54 | 531 | 2013/12/11] |
| 55 | | |
| 56 | | |
| 57 | | |
| 58 50 | | |
| 59 60 | | For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml |
| 00 | | |

| 1 | | |
|----------|-----|---|
| 2 | | |
| 3 | 532 | 30. Israel E, Cardet JC, Carroll JK, et al. Reliever-Triggered Inhaled Glucocorticoid in Black and Latinx |
| 4 | 533 | Adults with Asthma. <i>N Engl J Med</i> 2022 doi: 10.1056/NEJMoa2118813 [published Online First: |
| 5 | 534 | 2022/02/26] |
| 6 | 535 | 31. Israel E, Cardet JC, Carroll JK, et al. A randomized, open-label, pragmatic study to assess reliever- |
| 7 | 536 | triggered inhaled corticosteroid in African American/Black and Hispanic/Latinx adults with |
| 8 9 | 537 | asthma: design and methods of the PREPARE trial. <i>Contemporary Clinical Trials</i> 2021;101, |
| 10 | 538 | 106246 doi: 10.1016/j.cct.2020.106246 |
| 11 | 539 | 32. Definition and DDLs for the OMOP Common Data Model (CDM) 2022 [updated Auguest, 2022. |
| 12 | 540 | Available from: <u>https://github.com/OHDSI/CommonDataModel</u> accessed September 20 2022. |
| 13 | 541 | 33. Linear Mixed Models in Practice: A SAS-Oriented Approach: Springer Science & Business Media 2012 |
| 14 | 542 | 34. Garcia TP, Marder K. Statistical Approaches to Longitudinal Data Analysis in Neurodegenerative |
| 15 | 543 | Diseases: Huntington's Disease as a Model. Current Neurology and Neuroscience Reports |
| 16 17 | 544 | 2017;17(2):14. doi: 10.1007/s11910-017-0723-4 |
| 17 18 | 545 | 35. Raudenbush SW, Bryk AS. Hierarchical Linear Models: Applications and Data Analysis Methods. 2nd |
| 19 | 546 | ed. Thousand Oaks, CA: Sage Publications 2002. |
| 20 | 547 | 36. Salciccioli JD, She L, Tulchinsky A, et al. Effect of COVID-19 on asthma exacerbation. J Allergy Clin |
| 21 | 548 | <i>Immunol Pract</i> 2021;9(7):2896-99.e1. doi: 10.1016/j.jaip.2021.04.038 [published Online First: |
| 22 | 549 | 2021/05/04] |
| 23 | 550 | 37. American Academy of Asthma al. Asthma IQ: patient management and outcomes [Available from: |
| 24 | 551 | https://education.aaaai.org/AIQMgmtOutcomes accessed August 23 2022. |
| 25 26 | 552 | |
| 20 27 | | |
| 28 | | |
| 29 | | |
| 30 | | |
| 31 | | |
| 32 | | |
| 33 34 | | |
| 35 | | |
| 36 | | |
| 37 | | |
| 38 | | |
| 39 | | |
| 40 | | |
| 41 42 | | |
| 43 | | |
| 44 | | |
| 45 | | |
| 46 | | |
| 47 | | |
| 48 | | |
| 49 50 | | |
| 50 51 | | |
| 52 | | |
| 53 | | |
| 54 | | |
| 55 | | |
| 56 | | |
| 57 | | |

| 2 | | |
|----------|----|---|
| 3 | 1 | Supplemental Materials |
| 4 | 2 | |
| 5 | 3 | Hierarchy of Controller Step Levels |
| 6 7 | 4 | |
| 8 | 5 | Step 2 |
| 9 | 6 | Low dose ICS |
| 10 | 7 | Step 3 |
| 11 | 8 | Low dose ICS plus Leukotriene inhibitor |
| 12 | 9 | Medium dose ICS |
| 13 | 10 | Low dose ICS plus LABA OR LAMA |
| 14 | 11 | ○ High dose ICS |
| 15 | 12 | • Step 4 |
| 16 | 13 | Medium dose ICS plus Leukotriene inhibitor |
| 17 | 14 | Low dose ICS plus LABA OR LAMA plus Leukotriene inhibitor |
| 18 | 15 | Low dose ICS plus LABA AND LAMA |
| 19 | 16 | Low dose ICS plus LABA AND LAMA plus Leukotriene inhibitor |
| 20 | 17 | High dose ICS plus Leukotriene inhibitor |
| 21 | 18 | Medium dose ICS plus LABA OR LAMA |
| 22 | 19 | Medium dose ICS plus LABA OR LAMA plus Leukotriene inhibitor |
| 23 | 20 | • Step 5 |
| 24 | 21 | Medium dose ICS plus LABA AND LAMA |
| 25 | 22 | Medium dose ICS plus LABA AND LAMA plus Leukotriene inhibitor |
| 26 | 23 | High dose ICS plus LABA OR LAMA |
| 27 29 | 24 | High dose ICS plus LABA AND LAMA |
| 28 | 25 | High dose ICS plus LABA OR LAMA plus Leukotriene inhibitor |
| 29 30 | 26 | High dose ICS plus LABA AND LABA plus Leukotriene inhibitor |
| 30 31 | 20 | Step 6 |
| 32 | 28 | |
| 33 | 20 | |
| 34 | 30 | Daily Corticosteroids |
| 35 | 31 | Overall Model for All 28 Months (Supplemental Table 1; no corrections applied; no spline) |
| 36 | 32 | |
| 37 | 33 | The month before or after enrollment did show a significant increase over time (estimate: 0.039; |
| 38 | 34 | t = 9.315). The UCare patients were at a significantly higher asthma controller medication level |
| 39 | 35 | overall (difference: 0.191; t = 2.327). The assigned reclassified levels differed significantly |
| 40 | 36 | between the sites (F(15, 692.810) = 19.968 ; p = 0.000). Five sites (Sites 2, 3, 4, 5, 7) had |
| 41 | 37 | significantly higher steps of asthma controller medications than patients from Site 16. Two sites |
| 42 | 38 | (Sites 6, 15) had significantly lower steps of asthma controller medications than patients from |
| 43 | 39 | Site 16. The assigned reclassified levels differed significantly with the patients' decade of birth |
| 44 | 40 | (F(4, 692.014) = 5.135; p = 0.000). Patients born in the 1940s/1950s had significantly higher |
| 45 | 41 | levels of asthma controller medications than patients born in the 1990s/2000s (difference: |
| 46 | 42 | 0.611; t = 3.803). Lastly, in the months were COVID-19 was not present (before April 2020), the |
| 47 | 43 | patients had a significantly higher asthma controller medication level than after the COVID-19 |
| 48 40 | 44 | pandemic began (difference: 0.902; t = 14.118; Supplemental Table 1). |
| 49 50 | 45 | pandemic began (difference: 0.902, t = 14.110, Supplemental Table 1). |
| 50 | 46 | |
| 52 | 40 | |
| 53 | | |
| 54 | | |
| 55 | | |
| 56 | | |
| 57 | | |
| 58 | | |
| 59 | | 1 |
| 60 | | For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml |

1 2 3

4

5

6

7

8

9

10

11

12

13 14

15

16

17

18

19

20

21

22

23

24 25

26

27

28

29

30

31

32

33

34

35

36 37

38

39

40

41

42

t

3.24*

9.32*

2.33*

-1.27

3.80*

6.49*

3.49*

5.24*

-4.25*

3.02*

0.13

1.11

0.19

0.43

-0.58

-0.33

0.78

-4.05*

3.80*

1.29

1.54

1.80 +

14.19*

| Supplemental Table 1. Fin | 1 | U | | | |
|-------------------------------|----------------------------|--------------------|-----------------------|--|--|
| Parameter | Estimate | Standard Error | 95% CI | | |
| | | og Likelihood: 736 | | | |
| | | 0.37) = 86.77; p < | | | |
| | | 91.99) = 5.41; p = | | | |
| | | .81) = 19.97; p < | | | |
| | ecade of Birth: F(4 | | | | |
| | D Correction: F(1, 0.78 | 0.24 | | | |
| Intercept (Baseline) Month | 0.78 | 0.24 | [0.31, 1.25] | | |
| UCare | 0.04 | 0.00 | [0.03, 0.05] | | |
| PARTICS | 0.19 | | [0.03, 0.35] rence | | |
| Site 1 | -0.44 | 0.34 | [-1.11, 0.24] | | |
| Site 1 | 1.14 | 0.34 | [0.55, 1.73] | | |
| Site 3 | 1.51 | 0.23 | [1.05, 1.96] | | |
| Site 3 | 0.91 | 0.26 | [0.40, 1.42] | | |
| Site 5 | 1.22 | 0.20 | [0.76, 1.68] | | |
| Site 6 | -0.93 | 0.23 | [-1.36, -0.50] | | |
| Site 7 | 0.66 | 0.22 | [0.23, 1.08] | | |
| Site 8 | 0.04 | 0.33 | [-0.61, 0.69] | | |
| Site 9 | 0.27 | 0.24 | [-0.21, 0.74] | | |
| Site 10 | 0.05 | 0.23 | [-0.41, 0.50] | | |
| Site 11 | 0.11 | 0.25 | [-0.38, 0.60] | | |
| Site 12 | -0.24 | 0.41 | [-1.04, 0.57] | | |
| Site 13 | -0.07 | 0.23 | [-0.51, 0.37] | | |
| Site 14 | 0.17 | 0.23 | [-0.27, 0.62] | | |
| Site 15 | -1.43 | 0.35 | [-2.13, -0.74] | | |
| Site 16 | | | rence | | |
| Born: 1940s & 1950s | 0.61 | 0.16 | [0.30, 0.93] | | |
| Born: 1960s | 0.21 | 0.16 | [-0.11, 0.52] | | |
| Born: 1970s | 0.26 | 0.17 | [-0.07, 0.58] | | |
| Born: 1980s | 0.31 | 0.17 | [-0.03, 0.65] | | |
| Born: 1990s & 2000s | | Refei | rence | | |
| No COVID-19 | 0.90 | 0.06 | [0.78, 1.03] | | |
| COVID-19 Present | | Refei | rence | | |
| * p-value < 0.05 | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |

48

49

4.26*

2.30*

1.35

1.11

4.79*

5.08*

2.26*

3.82*

-0.87

-0.08

-1.56

4.82*

0.78

3.50*

0.19

-1.38

6.34*

-0.53

0.40

2.97*

0.69

0.97

0.32

-0.79

1.49

3.51*

| Supplemental Table 2. LM | | | 1.07550.44 | |
|--------------------------------------|---|--------------------|-------------------------------|--|
| All V | ariables (-2 Restri | • | | |
| Month: F(1, 694.89) = 5.31; p = 0.02 | | | | |
| | | (5.15) = 1.81; p = | | |
| | | l.21) = 18.76; p = | | |
| | • | 01.07) = 0.16; p = | | |
| | ecade of Birth: F(4 | • | • | |
| | Race/Ethnicity: F(| , , . | • | |
| COV | Language: F(1, 695.91) = 2.22; p = 0.14 COVID Correction: F(1, 12122.12) = 12.28; p = 0. | | | |
| Intercept (Baseline) | 4.57 | 1.07 | [2.46, 6.67] | |
| Month | 0.03 | 0.01 | [0.00, 0.05] | |
| UCare | 0.41 | 0.30 | [-0.19, 1.00] | |
| PARTICS | 0.11 | Refer | | |
| Site 1 | 1.43 | 1.29 | [-1.10, 3.96] | |
| Site 2 | 5.35 | 1.12 | [3.16, 7.53] | |
| Site 3 | 4.43 | 0.87 | [2.72, 6.15] | |
| Site 4 | 2.42 | 1.07 | [0.32, 4.53] | |
| Site 5 | 3.71 | 0.97 | [1.80, 5.61] | |
| Site 6 | -0.74 | 0.85 | [-2.41, 0.93] | |
| Site 7 | -0.07 | 0.83 | [-1.69, 1.55] | |
| Site 8 | -1.88 | 1.21 | [-4.24, 0.49] | |
| Site 9 | 4.93 | 1.02 | [2.93, 6.94] | |
| Site 10 | 0.75 | 0.96 | [-1.14, 2.65] | |
| Site 11 | 3.53 | 1.01 | [1.55, 5.52] | |
| Site 12 | 0.30 | 1.55 | | |
| Site 13 | -1.29 | 0.94 | [-2.74, 3.33] | |
| Site 14 | | | [-3.14, 0.55] | |
| Site 15 | 6.08 -0.75 | 0.96 | [4.20, 7.96] [-3.56, 2.06] | |
| Site 16 | -0.75 | Refer | | |
| Male | 0.16 | 0.40 | | |
| | 0.10 | | [-0.63, 0.95] | |
| Female Born: 1940s & 1950s | 1.77 | Refer | | |
| | 0.40 | 0.60 0.59 | [0.60, 2.95] [-0.75, 1.56] | |
| Born: 1960s Born: 1970s | | | - | |
| Born: 1980s | 0.60 | 0.61 | [-0.61, 1.80] | |
| | 0.20 | 0.63 | [-1.04, 1.45] | |
| Born: 1990s & 2000s | -0.37 | Refer 0.47 | | |
| Hispanic Nan Uianania | -0.37 | | [-1.29, 0.55] | |
| Non-Hispanic | 0.00 | Refer | | |
| English | 0.82 | 0.55 | [-0.26, 1.89] | |
| Spanish | 0.50 | Refer | | |
| No COVID-19 | 0.59 | 0.17 | [0.26, 0.92] | |
| COVID-19 Present | | Refer | ence | |